[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"OrganOx Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":219},{"warningLetters":4,"total":218},[5,32,54,74,100,121,142,162,182,200],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},2698,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-05-03T13:20:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-11T05:00:00Z\">02\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frenas-organic-613036-02112022\">Rena&#039;s Organic \u003C\u002Fa>","Office of Human and Animal Food Operations East Division IV","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products\u003Cbr \u002F>\r\n","","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Dietary Supplements\u003Cbr>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rena S. Greenberg\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Registered Agent\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rena's Organic \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>414 26th St West\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bradenton\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>34205-4926\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:SUPPORT@renasorganic.com\"> SUPPORT@renasorganic.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East Division IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>22-HAFE4-WL-02\u002FCMS No. 613036\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Greenberg:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.renasorganic.com in February 2022 and has determined that you take orders there for the products “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” “CBD Super Food,” and “Rena’s Organic For Pets 300mg CBD,” all of which you promote as products containing cannabidiol (CBD). We have also reviewed your social media websites at www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic; these websites direct consumers to your website, www.renasorganics.com to purchase your products. The claims on your website and social media websites establish that your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1). FDA has\u003Cbr>\n\u003Cbr>\nalso determined that your “Rena’s Organic For Pets 300mg CBD” product is an unapproved new animal drug that is unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Human Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website and your social media websites, your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website https:\u002F\u002Frenasorganic.com and your social media website https:\u002F\u002Fwww.facebook.com\u002FRenasOrganic\u002F that establish the intended use of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On the Blog post, “3 Reasons to Be Excited About CBD!” dated January 15, 2021:\u003Cbr>\n• “Cancer-Fighting Capabilities . . . recent studies have shown that CBD can act as a direct antitumor agent for a variety of aggressive cancers and can even prevent the spread of cancer cells in the body.”\u003Cbr>\n• “Potential for Neurodegenerative Disorders and Brain Injury . . . CBD has various neuroprotective effects that have shown effectiveness against neural cell damage related to various neurodegenerative disorders such as Alzheimer’s. CBD consumption can limit or prevent the damage caused by the advancing disease and even slow down the progression of degenerative brain diseases. Studies are also being conducted to conclusively prove the benefit of administering CBD immediately after traumatic brain injuries or spinal cord injuries to prevent the release of harmful mediators that often lead to permanent brain damage in such scenarios.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled, “CBD Oil: Can It Treat Opioid Dependency?” linked from your Facebook post dated October 10, 2020 (which states “Opioid addiction kills 130 people in the USA every day. The medical community believes that CBD can curb opioid dependence in the country.”):\u003C\u002Fp>\n\n\u003Cp>• “CBD is being touted as a safer alternative to opioids in the market. Unlike opioids, CBD isn’t addictive and doesn’t have psychoactive properties. Preliminary studies show that CBD can reduce opioid cravings, and that it breaks the addiction cycle.”\u003C\u002Fp>\n\n\u003Cp>• “Seeing how CBD effectively manages pain, many healthcare providers have started recommending it to patients suffering from chronic pain and undergoing chemotherapy.”\u003C\u002Fp>\n\n\u003Cp>• “Prevents Relapse . . . According to preclinical studies, the therapeutic properties of CBD can reduce cravings for psychostimulants, opioids and hard drugs like cocaine. CBD also rewires the brain’s programming to lower the intensity of cravings, making it easier to break the opioid addiction.”\u003C\u002Fp>\n\n\u003Cp>On the Blog post, “How CBD Can Help You Quit Smoking” dated August 27, 2020:\u003C\u002Fp>\n\n\u003Cp>• “CBD can help you with smoking cessation. There’s mounting evidence that suggests that CBD can decrease the urge to smoke, until it disappears altogether.”\u003C\u002Fp>\n\n\u003Cp>• “According to studies, CBD oil can help weaken habitual triggers and breaks the addictive association with time, allowing smokers to quit.”\u003C\u002Fp>\n\n\u003Cp>• “Preventing Relapse . . . While there still isn’t enough research to confidently say that CBD oil can eliminate nicotine addiction, ongoing studies have proven that it can be used to prevent relapses when quitting cocaine and morphine.”\u003C\u002Fp>\n\n\u003Cp>• “Combating Nicotine Withdrawal . . . CBD triggers the release of serotonin by reacting with 5-HT1A receptors in the brain (just like antidepressants) and prevents anxiety, stress and moodiness caused by quitting smoking.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled, “CBD Oil: Can it Help ADHD Patients?” linked from your Facebook post dated October 23, 2020:\u003C\u002Fp>\n\n\u003Cp>• “CBD is especially useful in releasing serotonin in the body to combat feelings of anxiety and stress. Increased levels of serotonin in the body help us feel more relaxed and boost concentration—this is why many patients believe CBD can treat ADHD.”\u003C\u002Fp>\n\n\u003Cp>• “CBD is a much safer alternative to conventional ADHD treatment. It’s all-natural, and it reacts with our bodies inbuilt receptors to promote optimal functionality.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled, “Curing Insomnia with CBD” linked from your Facebook post dated October 24, 2020:\u003Cbr>\n\u003Cbr>\n• “Anxiety and insomnia go hand in hand. People who suffer from anxiety usually struggle with insomnia. Treating anxiety through therapy, medication, or CBD can help people sleep better.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled, “What is CBD?”:\u003C\u002Fp>\n\n\u003Cp>• “At Rena’s Organic, I want you to share with you the truth about CBD and its amazing properties. That’s because I want you and your loved ones to have an alternative to risky and debilitating pills and opioids.”\u003C\u002Fp>\n\n\u003Cp>On the Blog post, “How to Use CBD to Combat Holiday Stress” dated January 22, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Reduced Anxiety and Depression . . . Studies show that cannabidiol has anxiolytic-like and anti-depressant-like effects, which can help reduce anxiety and depression in many people. While more research is required to prove the therapeutic effects of CBD, there are several studies that suggest that CBD can help alleviate some symptoms of depression and make the condition easier to manage.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled, “Using CBD Oil for the Symptoms of Fibromyalgia” linked from your Facebook post dated February 9, 2021:\u003C\u002Fp>\n\n\u003Cp>• “CBD oil has helped countless patients gain relief from the debilitating symptoms of fibromyalgia.”\u003C\u002Fp>\n\n\u003Cp>• “According to a 2020 review, CBD oil has proven to . . . reduce inflammation, and relieve chronic pain. CBD also helps with . . . anxiety, which can keep people from achieving a state of complete rest.”\u003C\u002Fp>\n\n\u003Cp>On the product page for “CBD Super Cider”:\u003C\u002Fp>\n\n\u003Cp>• “Curbs Cravings”\u003C\u002Fp>\n\n\u003Cp>• “Helichrysum [an ingredient in CBD Super Cider] is a powerful compound that works on your Endo-cannabinoid system. It is know [sic] to be a potent:\u003Cbr>\n&nbsp; o Anti-depressant\u003Cbr>\n&nbsp; o Mood stabilizer\u003Cbr>\n&nbsp; o Inflammation Fighter”\u003C\u002Fp>\n\n\u003Cp>• “Orange Essential Oil [an ingredient in CBD Super Cider] may naturally relieve anxiety, . . . depression and inflammation of the body.”\u003C\u002Fp>\n\n\u003Cp>Your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>External Analgesic Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are topical products intended for use as external analgesics, among other uses. As described below, these external analgesic drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>As previously noted, in general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” drug products.\u003C\u002Fp>\n\n\u003Cp>“500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are external analgesic drug products subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical products intended for use as an external analgesic are deemed to be GRASE and not a “new drug” if, among other things, they conform to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. The 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order by section 505G(b)(8) of the FD&amp;C Act. However, your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products do not conform to the conditions of use specified in the final administrative order, because the products’ active ingredient, CBD, is not an active ingredient in such order (nor in any applicable final monograph or TFM).\u003C\u002Fp>\n\n\u003Cp>Although CBD is listed as an inactive ingredient in the labels of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products, the product labeling clearly represents CBD as an active ingredient, which is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body (see 21 CFR 201.66(b)(2)). For instance, your product labels and website repeatedly highlight the use of CBD for various conditions (see above claims), include numerous references to CBD with images of cannabis plants; and prominently feature CBD on the principal display panels of all of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products. CBD is not a permitted active ingredient under the 1983 TFM.\u003C\u002Fp>\n\n\u003Cp>Even if CBD could be considered an inactive ingredient in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products, these products would still need an approved drug application to be legally marketed because they would not meet the requirements for marketing under section 505G of the FD&amp;C Act. In particular, these products would not meet the conditions under section 505G(a)(1), insofar as they would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD, however, has known pharmacological activity with demonstrated risks.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> It is unknown whether the levels of CBD used in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products have pharmacological activity or pose any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” product, that product would not meet the general requirements for nonprescription drugs needed for legal marketing under sections 505G(a)(1). Thus, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” do not meet requirements under section 505G of the FD&amp;C Act, under which they would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Human Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are also misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Furthermore, your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products are also misbranded under section 502(a) of the FD&amp;C Act because the labeling of these products is false and misleading for several reasons. First, the labeling for these products identifies CBD as an inactive ingredient but represents CBD as having purported active pharmacological properties such as pain relief, among others. Even if CBD could be considered an inactive ingredient in these products, the prominent featuring of CBD on the labeling of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products causes the products to be misbranded under section 502(a) of the FD&amp;C Act, which deems a drug to be misbranded if its labeling is “false or misleading in any particular,” and under 21 CFR 201.10(c)(4). Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason . . . [of] the featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>301(ll) and Adulterated Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that some of your products appear to be promoted or labeled as conventional foods. For example, your “CBD Super Cider” product is promoted as having a “delicious taste” and that it will not “have that sickeningly, sweet taste that most drinks offer.” Additionally, your “CBD Super Cider” and “CBD SuperFood” products are labeled with a Nutrition Facts label. Your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture” and “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture” products, which are taken sublingually, also bear a Nutrition Facts label. However, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your “CBD Super Cider” and “CBD SuperFood” products are foods to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of those products is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Many unanswered questions and data gaps about CBD toxicity exist, and some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in conventional food products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our review of your website, www.renasorganic.com, and your social media websites, www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic, FDA determined that your firm is marketing the unapproved new animal drug “Rena’s Organic For Pets 300mg CBD.” Based on our review of your website and social media websites, your “Rena’s Organic For Pets 300mg CBD” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, this product is an unapproved new animal drug and marketing it violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website www.renasorganic.com, and your social media websites, www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic, that establish the intended use of your “Rena’s Organic For Pets 300mg CBD” as a drug include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Rena’s Organic For Pets 300mg CBD” at https:\u002F\u002Frenasorganic.com\u002Fproducts\u002Frenas-organic-for-pets\u002F:\u003C\u002Fp>\n\n\u003Cp>• “Whatever ailment your pet is suffering from, CBD or Cannabidiol, has shown extremely promising results.”\u003C\u002Fp>\n\n\u003Cp>On your blog post titled “4 Uses for CBD for Your Pets” at https:\u002F\u002Frenasorganic.com\u002F4-uses-for-cbd-for-your-pets\u002F:\u003C\u002Fp>\n\n\u003Cp>• “Small scale studies have shown that CBD can help calm anxious pets without compromising their health, so they’re easier to manage.”\u003C\u002Fp>\n\n\u003Cp>• “Let’s look at some of the uses of CBD for your pets:\u003C\u002Fp>\n\n\u003Cp>1. CBD as a Painkiller\u003Cbr>\nCBD is known for its anti-inflammatory properties that make it an effective painkiller for humans and animals. If your pet was injured in an accident, try massaging the effective area with potent CBD oils to reduce the\u003Cbr>\ninflammation and pain. . . .\u003C\u002Fp>\n\n\u003Cp>2. CBD is an Anticonvulsant\u003Cbr>\nIt’s not very common, but pets can have seizures too. Seeing your pet have a seizure is the traumatizing, to say the least. If your pet has a condition that causes seizures or tremors, use CBD to reduce them. CBD is an anticonvulsant; it’s proven to be very effective at treating epilepsy and other similar conditions.\u003C\u002Fp>\n\n\u003Cp>3. CBD for Anxiety and Stress\u003Cbr>\nOwners struggling to manage an anxious pet can use CBD to calm them down. Both dogs and pets can suffer from anxiety in the same way humans do. If you notice that your pet hides in one corner of the house or gets aggressive when you’re trying to leave the house, you can use CBD to put them at ease. CBD relaxes animals by reducing stress and anxiety.\u003C\u002Fp>\n\n\u003Cp>4. CBD as an Antiemetic\u003Cbr>\nIs your pet vomiting everywhere due to certain illnesses? Try giving them some CBD brands ; it’s a known antiemetic and can help control nausea and vomiting. Your “Rena’s Organic for Pets” website metadata includes the following tag:\u003Cbr>\n• “product_tag-dog-cancer-cbd”\u003Cbr>\n\u003Cbr>\nOn your webpage titled, “What is CBD?” at https:\u002F\u002Frenasorganic.com\u002Fwhat-is-cbd\u002F:\u003C\u002Fp>\n\n\u003Cp>• “Many pet owners are faced with watching their pets suffer from many of the same diseases that humans are inflicted with. There are more and more reports of animals being treated for these and other ailments successfully with CBD.”\u003C\u002Fp>\n\n\u003Cp>On your January 12, 2021 Facebook post www.facebook.com\u002FRenasOrganic:\u003C\u002Fp>\n\n\u003Cp>• “If something is making your pet anxious or tense, use our organic CBD Pet Product to help soothe them:”\u003C\u002Fp>\n\n\u003Cp>On your January 6, 2021 Instagram post at www.instagram.com\u002Frenasorganic:\u003C\u002Fp>\n\n\u003Cp>• “Try using our CBD product for pets. It can help reduce anxiety and calm down your furry companions. #CBD #CBDProducts #CBDforPainRelief #CBDforAnxiety #CBDforArthritis #CBDforStress #StressRelief #Anxiety”\u003C\u002Fp>\n\n\u003Cp>Your “Rena’s Organic For Pets 300mg CBD” product is a “new animal drug” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-l. This product is not approved or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of this adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above violations. Please notify this office in writing within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot completely address any violations within fifteen working days, state the reasons for the delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact, Ms. Marilyn Santiago, Compliance Officer, at (787) 729-8707 or via email at Marilyn.santiago@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director | FDA San Juan District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations-\u003Cbr>\nEast Division\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity\".\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \"\u003Cem>Using the Inactive Ingredient Database\u003C\u002Fem>\" Guidance for Industry (July 2019), p. 1 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload\u003C\u002Fa>, and \"\u003Cem>Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\u003C\u002Fem>\" Guidance for Industry (May 2005), pp. 1-2 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man”. All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 330.1(e).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cem>\u003Cstrong>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fstrong>\u003C\u002Fem>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDietary Supplements\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Rena S. Greenberg\n\nRecipient Title\n\nRegistered Agent\n\nRena's Organic\n\n414 26th St West\n\nBradenton, FL 34205-4926\n\nUnited States\n\nSUPPORT@renasorganic.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East Division IV\n\nUnited States\n\nWARNING LETTER\n\n22-HAFE4-WL-02\u002FCMS No. 613036\n\nDear Ms. Greenberg:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.renasorganic.com in February 2022 and has determined that you take orders there for the products “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” “CBD Super Food,” and “Rena’s Organic For Pets 300mg CBD,” all of which you promote as products containing cannabidiol (CBD). We have also reviewed your social media websites at www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic; these websites direct consumers to your website, www.renasorganics.com to purchase your products. The claims on your website and social media websites establish that your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). FDA has\n\nalso determined that your “Rena’s Organic For Pets 300mg CBD” product is an unapproved new animal drug that is unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nUnapproved New Human Drugs\n\nBased on our review of your website and your social media websites, your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on your website https:\u002F\u002Frenasorganic.com and your social media website https:\u002F\u002Fwww.facebook.com\u002FRenasOrganic\u002F that establish the intended use of your products as drugs include, but may not be limited to, the following:\n\nOn the Blog post, “3 Reasons to Be Excited About CBD!” dated January 15, 2021:\n\n• “Cancer-Fighting Capabilities . . . recent studies have shown that CBD can act as a direct antitumor agent for a variety of aggressive cancers and can even prevent the spread of cancer cells in the body.”\n\n• “Potential for Neurodegenerative Disorders and Brain Injury . . . CBD has various neuroprotective effects that have shown effectiveness against neural cell damage related to various neurodegenerative disorders such as Alzheimer’s. CBD consumption can limit or prevent the damage caused by the advancing disease and even slow down the progression of degenerative brain diseases. Studies are also being conducted to conclusively prove the benefit of administering CBD immediately after traumatic brain injuries or spinal cord injuries to prevent the release of harmful mediators that often lead to permanent brain damage in such scenarios.”\n\nOn the webpage titled, “CBD Oil: Can It Treat Opioid Dependency?” linked from your Facebook post dated October 10, 2020 (which states “Opioid addiction kills 130 people in the USA every day. The medical community believes that CBD can curb opioid dependence in the country.”):\n\n• “CBD is being touted as a safer alternative to opioids in the market. Unlike opioids, CBD isn’t addictive and doesn’t have psychoactive properties. Preliminary studies show that CBD can reduce opioid cravings, and that it breaks the addiction cycle.”\n\n• “Seeing how CBD effectively manages pain, many healthcare providers have started recommending it to patients suffering from chronic pain and undergoing chemotherapy.”\n\n• “Prevents Relapse . . . According to preclinical studies, the therapeutic properties of CBD can reduce cravings for psychostimulants, opioids and hard drugs like cocaine. CBD also rewires the brain’s programming to lower the intensity of cravings, making it easier to break the opioid addiction.”\n\nOn the Blog post, “How CBD Can Help You Quit Smoking” dated August 27, 2020:\n\n• “CBD can help you with smoking cessation. There’s mounting evidence that suggests that CBD can decrease the urge to smoke, until it disappears altogether.”\n\n• “According to studies, CBD oil can help weaken habitual triggers and breaks the addictive association with time, allowing smokers to quit.”\n\n• “Preventing Relapse . . . While there still isn’t enough research to confidently say that CBD oil can eliminate nicotine addiction, ongoing studies have proven that it can be used to prevent relapses when quitting cocaine and morphine.”\n\n• “Combating Nicotine Withdrawal . . . CBD triggers the release of serotonin by reacting with 5-HT1A receptors in the brain (just like antidepressants) and prevents anxiety, stress and moodiness caused by quitting smoking.”\n\nOn the webpage titled, “CBD Oil: Can it Help ADHD Patients?” linked from your Facebook post dated October 23, 2020:\n\n• “CBD is especially useful in releasing serotonin in the body to combat feelings of anxiety and stress. Increased levels of serotonin in the body help us feel more relaxed and boost concentration—this is why many patients believe CBD can treat ADHD.”\n\n• “CBD is a much safer alternative to conventional ADHD treatment. It’s all-natural, and it reacts with our bodies inbuilt receptors to promote optimal functionality.”\n\nOn the webpage titled, “Curing Insomnia with CBD” linked from your Facebook post dated October 24, 2020:\n\n• “Anxiety and insomnia go hand in hand. People who suffer from anxiety usually struggle with insomnia. Treating anxiety through therapy, medication, or CBD can help people sleep better.”\n\nOn the webpage titled, “What is CBD?”:\n\n• “At Rena’s Organic, I want you to share with you the truth about CBD and its amazing properties. That’s because I want you and your loved ones to have an alternative to risky and debilitating pills and opioids.”\n\nOn the Blog post, “How to Use CBD to Combat Holiday Stress” dated January 22, 2021:\n\n• “Reduced Anxiety and Depression . . . Studies show that cannabidiol has anxiolytic-like and anti-depressant-like effects, which can help reduce anxiety and depression in many people. While more research is required to prove the therapeutic effects of CBD, there are several studies that suggest that CBD can help alleviate some symptoms of depression and make the condition easier to manage.”\n\nOn the webpage titled, “Using CBD Oil for the Symptoms of Fibromyalgia” linked from your Facebook post dated February 9, 2021:\n\n• “CBD oil has helped countless patients gain relief from the debilitating symptoms of fibromyalgia.”\n\n• “According to a 2020 review, CBD oil has proven to . . . reduce inflammation, and relieve chronic pain. CBD also helps with . . . anxiety, which can keep people from achieving a state of complete rest.”\n\nOn the product page for “CBD Super Cider”:\n\n• “Curbs Cravings”\n\n• “Helichrysum [an ingredient in CBD Super Cider] is a powerful compound that works on your Endo-cannabinoid system. It is know [sic] to be a potent:\n\no Anti-depressant\n\no Mood stabilizer\n\no Inflammation Fighter”\n\n• “Orange Essential Oil [an ingredient in CBD Super Cider] may naturally relieve anxiety, . . . depression and inflammation of the body.”\n\nYour “300 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nExternal Analgesic Drug Products\n\nBased on the above labeling claims, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are topical products intended for use as external analgesics, among other uses. As described below, these external analgesic drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nAs previously noted, in general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” drug products.\n\n“500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are external analgesic drug products subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical products intended for use as an external analgesic are deemed to be GRASE and not a “new drug” if, among other things, they conform to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. The 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order by section 505G(b)(8) of the FD&C Act. However, your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products do not conform to the conditions of use specified in the final administrative order, because the products’ active ingredient, CBD, is not an active ingredient in such order (nor in any applicable final monograph or TFM).\n\nAlthough CBD is listed as an inactive ingredient in the labels of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products, the product labeling clearly represents CBD as an active ingredient, which is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body (see 21 CFR 201.66(b)(2)). For instance, your product labels and website repeatedly highlight the use of CBD for various conditions (see above claims), include numerous references to CBD with images of cannabis plants; and prominently feature CBD on the principal display panels of all of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products. CBD is not a permitted active ingredient under the 1983 TFM.\n\nEven if CBD could be considered an inactive ingredient in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products, these products would still need an approved drug application to be legally marketed because they would not meet the requirements for marketing under section 505G of the FD&C Act. In particular, these products would not meet the conditions under section 505G(a)(1), insofar as they would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.1 A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).2 CBD has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects3 and must be safe when used at the intended dosage.4 CBD, however, has known pharmacological activity with demonstrated risks.5 It is unknown whether the levels of CBD used in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products have pharmacological activity or pose any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” product, that product would not meet the general requirements for nonprescription drugs needed for legal marketing under sections 505G(a)(1). Thus, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” do not meet requirements under section 505G of the FD&C Act, under which they would be deemed to be GRASE and not a new drug.\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranded Human Drugs\n\nYour “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture,” “500 mg Pain Relief Cream,” “1000 mg Pain Relief Cream,” “1000 mg CBD Anti-Aging Beauty Cream,” “CBD Super Cider,” and “CBD Super Food” products are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nFurthermore, your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products are also misbranded under section 502(a) of the FD&C Act because the labeling of these products is false and misleading for several reasons. First, the labeling for these products identifies CBD as an inactive ingredient but represents CBD as having purported active pharmacological properties such as pain relief, among others. Even if CBD could be considered an inactive ingredient in these products, the prominent featuring of CBD on the labeling of your “500 mg Pain Relief Cream” and “1000 mg Pain Relief Cream” products causes the products to be misbranded under section 502(a) of the FD&C Act, which deems a drug to be misbranded if its labeling is “false or misleading in any particular,” and under 21 CFR 201.10(c)(4). Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason . . . [of] the featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.”\n\n301(ll) and Adulterated Foods\n\nWe note that some of your products appear to be promoted or labeled as conventional foods. For example, your “CBD Super Cider” product is promoted as having a “delicious taste” and that it will not “have that sickeningly, sweet taste that most drinks offer.” Additionally, your “CBD Super Cider” and “CBD SuperFood” products are labeled with a Nutrition Facts label. Your “300 mg CBD Full Spectrum Oil Cannabinoid Tincture”, “600 mg CBD Full Spectrum Oil Cannabinoid Tincture” and “1500 mg CBD Full Spectrum Oil Cannabinoid Tincture” products, which are taken sublingually, also bear a Nutrition Facts label. However, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public.6 Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nAccording to your product labeling, your “CBD Super Cider” and “CBD SuperFood” products are foods to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of those products is a prohibited act under section 301(ll) of the FD&C Act.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.7\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Many unanswered questions and data gaps about CBD toxicity exist, and some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in conventional food products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Animal Drugs\n\nDuring our review of your website, www.renasorganic.com, and your social media websites, www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic, FDA determined that your firm is marketing the unapproved new animal drug “Rena’s Organic For Pets 300mg CBD.” Based on our review of your website and social media websites, your “Rena’s Organic For Pets 300mg CBD” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, this product is an unapproved new animal drug and marketing it violates the FD&C Act.\n\nExamples of claims observed on your website www.renasorganic.com, and your social media websites, www.facebook.com\u002FRenasOrganic and www.instagram.com\u002Frenasorganic, that establish the intended use of your “Rena’s Organic For Pets 300mg CBD” as a drug include, but are not limited to, the following:\n\nOn your product webpage for “Rena’s Organic For Pets 300mg CBD” at https:\u002F\u002Frenasorganic.com\u002Fproducts\u002Frenas-organic-for-pets\u002F:\n\n• “Whatever ailment your pet is suffering from, CBD or Cannabidiol, has shown extremely promising results.”\n\nOn your blog post titled “4 Uses for CBD for Your Pets” at https:\u002F\u002Frenasorganic.com\u002F4-uses-for-cbd-for-your-pets\u002F:\n\n• “Small scale studies have shown that CBD can help calm anxious pets without compromising their health, so they’re easier to manage.”\n\n• “Let’s look at some of the uses of CBD for your pets:\n\n1. CBD as a Painkiller\n\nCBD is known for its anti-inflammatory properties that make it an effective painkiller for humans and animals. If your pet was injured in an accident, try massaging the effective area with potent CBD oils to reduce the\n\ninflammation and pain. . . .\n\n2. CBD is an Anticonvulsant\n\nIt’s not very common, but pets can have seizures too. Seeing your pet have a seizure is the traumatizing, to say the least. If your pet has a condition that causes seizures or tremors, use CBD to reduce them. CBD is an anticonvulsant; it’s proven to be very effective at treating epilepsy and other similar conditions.\n\n3. CBD for Anxiety and Stress\n\nOwners struggling to manage an anxious pet can use CBD to calm them down. Both dogs and pets can suffer from anxiety in the same way humans do. If you notice that your pet hides in one corner of the house or gets aggressive when you’re trying to leave the house, you can use CBD to put them at ease. CBD relaxes animals by reducing stress and anxiety.\n\n4. CBD as an Antiemetic\n\nIs your pet vomiting everywhere due to certain illnesses? Try giving them some CBD brands ; it’s a known antiemetic and can help control nausea and vomiting. Your “Rena’s Organic for Pets” website metadata includes the following tag:\n\n• “product_tag-dog-cancer-cbd”\n\nOn your webpage titled, “What is CBD?” at https:\u002F\u002Frenasorganic.com\u002Fwhat-is-cbd\u002F:\n\n• “Many pet owners are faced with watching their pets suffer from many of the same diseases that humans are inflicted with. There are more and more reports of animals being treated for these and other ailments successfully with CBD.”\n\nOn your January 12, 2021 Facebook post www.facebook.com\u002FRenasOrganic:\n\n• “If something is making your pet anxious or tense, use our organic CBD Pet Product to help soothe them:”\n\nOn your January 6, 2021 Instagram post at www.instagram.com\u002Frenasorganic:\n\n• “Try using our CBD product for pets. It can help reduce anxiety and calm down your furry companions. #CBD #CBDProducts #CBDforPainRelief #CBDforAnxiety #CBDforArthritis #CBDforStress #StressRelief #Anxiety”\n\nYour “Rena’s Organic For Pets 300mg CBD” product is a “new animal drug” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-l. This product is not approved or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of this adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above violations. Please notify this office in writing within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot completely address any violations within fifteen working days, state the reasons for the delay and your schedule for completion.\n\nYour written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact, Ms. Marilyn Santiago, Compliance Officer, at (787) 729-8707 or via email at Marilyn.santiago@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director | FDA San Juan District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations-\n\nEast Division\n\n________________________________\n\n1 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity\".\n\n2 See, e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\n\n3 See, e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man”. All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n4 See 21 CFR 330.1(e).\n\n5 For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\n\n6 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n7 Under section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","Rena's Organic","renas-organic-613036-02112022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frenas-organic-613036-02112022","2026-10-26T08:09:48.645212+00:00","Warning Letter","Issued","2022-05-03","613036","Animal & VeterinaryDietary SupplementsDrugsFood & Beverages","Ms. Rena S. Greenberg","2026-08-20T01:57:43.886+00:00","Via Email","2022-02-11",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},725,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-08-12T04:00:00Z\">08\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-06T04:00:00Z\">08\u002F06\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-care-organics-711000-08062025\">K &amp; Care Organics\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC\u003Cbr \u002F>\r\n","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Shirly Gutshtat, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Keren Elisar, Founder &amp; President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>K &amp; Care Organics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Simtat Hadayagim 2 St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mikhmoret\u003C\u002Fspan> \u003Cspan>4029700\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Israel\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@kcare.co.il\"> info@kcare.co.il  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 6, 2025\u003C\u002Fp>\u003Cp>RE: 711000\u003C\u002Fp>\u003Cp>Dear Ms. Gutshtat and Ms. Elisar:\u003C\u002Fp>\u003Cp>This letter is to advise you that on May 14th, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website https:\u002F\u002Fwww.botaobaby.com\u002F, for your “BOTAÓ GROW NATURALLY Kids Mineral Foam Spray” (hereinafter “BOTAÓ Kids Mineral Foam Spray”), “BOTAÓ GROW NATURALLY Baby Mineral Foam Spray” (hereinafter “BOTAÓ Baby Mineral Foam Spray”), and “SUN &amp; SHINE SPF 50+ BROAD SPECTRUM Mineral Sunscreen Mousse,” (hereinafter “SUN &amp; SHINE Sunscreen Mousse”) sunscreen drug products, which are available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>Your “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN &amp; SHINE Sunscreen Mousse” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the products’ labeling, including the most recent labeling submitted to FDA as part of drug listing pursuant to 21 CFR part 207, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>BOTAÓ Kids Mineral Foam Spray\u003C\u002Fu>”\u003C\u002Fp>\u003Cp>“\u003Cstrong>Uses\u003C\u002Fstrong> ∙ helps prevent sunburn…” [from your product label]\u003C\u002Fp>\u003Cp>“BOTAO Mineral Sunscreen Foam Spray SPF 50+ for Kids, blends Zinc Oxide, a natural mineral filter for broad spectrum protection…” [from your product label]\u003C\u002Fp>\u003Cp>“Contains Zinc Oxide, 100% natural mineral filter known to be safe for use on kids. Providing high protection from harmful UVA and UVB rays, BOTAO sunscreen Foam is gentle on the skin and easily absorbed…” [from your product website]\u003C\u002Fp>\u003Cp>“\u003Cu>BOTAÓ Baby Mineral Foam Spray\u003C\u002Fu>”\u003C\u002Fp>\u003Cp>“\u003Cstrong>Uses\u003C\u002Fstrong> ∙ helps prevent sunburn…” [from your product label]\u003C\u002Fp>\u003Cp>“BOTAO Mineral Sunscreen Foam for Babies Broad Spectrum SPF 50+, contains Zinc Oxide, a natural mineral filter known to be safe for use on babies…” [from your product label]\u003C\u002Fp>\u003Cp>“Contains Zinc Oxide, 100% natural mineral filter known to be safe for use on babies. Providing high protection from harmful UVA and UVB rays, BOTAO sunscreen is gentle on the skin and easily absorbed.” [from your product website]\u003C\u002Fp>\u003Cp>“\u003Cu>SUN &amp; SHINE Sunscreen Mousse\u003C\u002Fu>”\u003Cbr>“\u003Cstrong>Uses\u003C\u002Fstrong> ∙ helps prevent sunburn…” [from your product label]\u003Cbr>“Mineral Sunscreen Mousse Broad Spectrum SPF50+ Sunscreen For Face and Body” [from your product label]\u003C\u002Fp>\u003Cp>Based on the above labeling, your “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN &amp; SHINE Sunscreen Mousse” are intended for use as over-the-counter (OTC) sunscreen drug products. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your drug products. Section 505G of the FD&amp;C Act, 21 U.S.C. 355h, governs the marketing of nonprescription drugs that are marketed without an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, such as your products. Under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), a nonprescription drug is misbranded if the drug is subject to section 505G of the FD&amp;C Act, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>Section 505G of the FD&amp;C Act, 21 U.S.C. 355h, provides that certain nonprescription drugs are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if they, among other things, conform to the conditions in the applicable OTC monograph. In the case of OTC sunscreen drug products, the applicable OTC monograph is set forth in the final administrative order, OTC000006: Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020), which was deemed a final order by 505G(b)(8) and 505G(k)(2)(B).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, under section 505G(m)(2), “notwithstanding subsection [505G](a),” sunscreens in dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder may only be lawfully marketed, without an application approved under section 505 of the FD&amp;C Act, pursuant to an order issued under section 505G of the FD&amp;C Act.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing sunscreen in a foam (aka mousse) dosage form\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. As previously stated, there are no FDA-approved applications in effect for your drug products.\u003C\u002Fp>\u003Cp>Thus, even if your products were in conformity with the conditions set forth in M020 and all other applicable requirements to be deemed GRASE and not new drugs under section 505G(a)(1), they do not comply with the requirements under section 505G. Accordingly, “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN &amp; SHINE Sunscreen Mousse” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee).\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name and the unique identifier “711000” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See sections 505G(a)(1) and (2) of the FD&amp;C Act and see Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf. As required by section 505G(a)(2), M020 encompasses the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6204 at 6229-6230 (Feb. 26, 2019); see also 84 FR 6204 at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&amp;C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&amp;C Act. To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a foam (aka mousse) dosage form.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The principal display panels of your product labels, as well as other materials, use the terms “foam spray,” “foam,” and\u002For “mousse” to describe each of your products that are the subject of this letter. “Foam” is the dosage form term in United States Pharmacopeia (USP) general chapter &lt;1151&gt;, Pharmaceutical Dosage Forms, that best corresponds to your products; “mousse” is not used in that reference. Additionally, USP &lt;1151&gt; defines “foam” and “spray” as two distinct dosage forms. Images, video, and text regarding your products confirm that each of the products addressed in this letter meets USP’s definition of “foam”—i.e., each appears as a dispersion of gas in a liquid or solid continuous phase wherein the liquid or solid contains the drug substance and suitable excipients.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nShirly Gutshtat, CEO\n\nRecipient Title\n\nKeren Elisar, Founder & President\n\nK & Care Organics\n\nSimtat Hadayagim 2 St\n\nMikhmoret 4029700\n\nIsrael\n\ninfo@kcare.co.il\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nAugust 6, 2025\nRE: 711000\nDear Ms. Gutshtat and Ms. Elisar:\nThis letter is to advise you that on May 14th, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website https:\u002F\u002Fwww.botaobaby.com\u002F, for your “BOTAÓ GROW NATURALLY Kids Mineral Foam Spray” (hereinafter “BOTAÓ Kids Mineral Foam Spray”), “BOTAÓ GROW NATURALLY Baby Mineral Foam Spray” (hereinafter “BOTAÓ Baby Mineral Foam Spray”), and “SUN & SHINE SPF 50+ BROAD SPECTRUM Mineral Sunscreen Mousse,” (hereinafter “SUN & SHINE Sunscreen Mousse”) sunscreen drug products, which are available for purchase in the United States without a prescription.\nYour “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN & SHINE Sunscreen Mousse” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the products’ labeling, including the most recent labeling submitted to FDA as part of drug listing pursuant to 21 CFR part 207, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“BOTAÓ Kids Mineral Foam Spray”\n“Uses ∙ helps prevent sunburn…” [from your product label]\n“BOTAO Mineral Sunscreen Foam Spray SPF 50+ for Kids, blends Zinc Oxide, a natural mineral filter for broad spectrum protection…” [from your product label]\n“Contains Zinc Oxide, 100% natural mineral filter known to be safe for use on kids. Providing high protection from harmful UVA and UVB rays, BOTAO sunscreen Foam is gentle on the skin and easily absorbed…” [from your product website]\n“BOTAÓ Baby Mineral Foam Spray”\n“Uses ∙ helps prevent sunburn…” [from your product label]\n“BOTAO Mineral Sunscreen Foam for Babies Broad Spectrum SPF 50+, contains Zinc Oxide, a natural mineral filter known to be safe for use on babies…” [from your product label]\n“Contains Zinc Oxide, 100% natural mineral filter known to be safe for use on babies. Providing high protection from harmful UVA and UVB rays, BOTAO sunscreen is gentle on the skin and easily absorbed.” [from your product website]\n“SUN & SHINE Sunscreen Mousse”\n“Uses ∙ helps prevent sunburn…” [from your product label]\n“Mineral Sunscreen Mousse Broad Spectrum SPF50+ Sunscreen For Face and Body” [from your product label]\nBased on the above labeling, your “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN & SHINE Sunscreen Mousse” are intended for use as over-the-counter (OTC) sunscreen drug products. No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your drug products. Section 505G of the FD&C Act, 21 U.S.C. 355h, governs the marketing of nonprescription drugs that are marketed without an approved application under section 505 of the FD&C Act, 21 U.S.C. 355, such as your products. Under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), a nonprescription drug is misbranded if the drug is subject to section 505G of the FD&C Act, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nSection 505G of the FD&C Act, 21 U.S.C. 355h, provides that certain nonprescription drugs are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if they, among other things, conform to the conditions in the applicable OTC monograph. In the case of OTC sunscreen drug products, the applicable OTC monograph is set forth in the final administrative order, OTC000006: Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020), which was deemed a final order by 505G(b)(8) and 505G(k)(2)(B).1 However, under section 505G(m)(2), “notwithstanding subsection [505G](a),” sunscreens in dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder may only be lawfully marketed, without an application approved under section 505 of the FD&C Act, pursuant to an order issued under section 505G of the FD&C Act.2 To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing sunscreen in a foam (aka mousse) dosage form3. As previously stated, there are no FDA-approved applications in effect for your drug products.\nThus, even if your products were in conformity with the conditions set forth in M020 and all other applicable requirements to be deemed GRASE and not new drugs under section 505G(a)(1), they do not comply with the requirements under section 505G. Accordingly, “BOTAÓ Kids Mineral Foam Spray,” “BOTAÓ Baby Mineral Foam Spray,” and “SUN & SHINE Sunscreen Mousse” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee).\nThe introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name and the unique identifier “711000” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 See sections 505G(a)(1) and (2) of the FD&C Act and see Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf. As required by section 505G(a)(2), M020 encompasses the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations.\n2 Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6204 at 6229-6230 (Feb. 26, 2019); see also 84 FR 6204 at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&C Act. To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a foam (aka mousse) dosage form.\n3 The principal display panels of your product labels, as well as other materials, use the terms “foam spray,” “foam,” and\u002For “mousse” to describe each of your products that are the subject of this letter. “Foam” is the dosage form term in United States Pharmacopeia (USP) general chapter \u003C1151>, Pharmaceutical Dosage Forms, that best corresponds to your products; “mousse” is not used in that reference. Additionally, USP \u003C1151> defines “foam” and “spray” as two distinct dosage forms. Images, video, and text regarding your products confirm that each of the products addressed in this letter meets USP’s definition of “foam”—i.e., each appears as a dispersion of gas in a liquid or solid continuous phase wherein the liquid or solid contains the drug substance and suitable excipients.","K & Care Organics","k-care-organics-711000-08062025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-care-organics-711000-08062025","2026-10-26T08:09:07.157322+00:00","2025-08-12","711000","Drugs Over-the-Counter Drugs","Shirly Gutshtat, CEO","2026-08-19T16:30:35.637+00:00","2025-08-06",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":19,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":24,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":20,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":73,"medical_device_id":20,"response_letter_date":20},2790,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2022-03-29T14:00:00Z\">03\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-28T04:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fheavens-organic-llc-627359-03282022\">Heaven’s Organic LLC \u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Angela Sidders and David Sidders\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Heaven’s Organic LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1324 Seven Springs Boulevard, #336\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Trinity\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>34655\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@heavensorganics.com\"> info@heavensorganics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 627359\u003C\u002Fp>\n\n\u003Cp>Date: March 28, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fheavensorganics.com\u002F on February 15, 2022, and March 9, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FHeavensOrganics\u002F, https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F, and https:\u002F\u002Ftwitter.com\u002Fheavensorganics, where you direct consumers to your website, https:\u002F\u002Fheavensorganics.com\u002F, to purchase your products. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003Cbr>\n\u003Cbr>\nSome examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Brand new research is showing that CBD could fight COVID-19. Check it out on Forbes” along with the image of text stating “New Study: Cannabis Compound CBD May Potentially Prevent, Fight COVID-19 Infection . . . anecdotal evidence suggests that people . . . who were prescribed regular high-potency doses of pharmaceutical-grade CBD were less likely to contract COVID . . . ‘Our research suggest that CBD . . . can block SARS-Cov-2 infection at early and even later stages of infection. . .’” [From January 25, 2022 posts on your social media websites https:\u002F\u002Fwww.facebook.com\u002FHeavensOrganics\u002F and https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F]\u003C\u002Fli>\n\t\u003Cli>“And in a first that shows CBD’s potential in fighting COVID-19 in people, Americans prescribed high-potency CBD oil showed lower rates of infection” [From a January 25, 2022 post on your social media website https:\u002F\u002Ftwitter.com\u002Fheavensorganics]\u003C\u002Fli>\n\t\u003Cli>“[H]eavensorganics #covid #covid19 #cbdhelps #cbdoil #naturesremedies #naturalremedy #natureheals” [From a January 25, 2022 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAngela Sidders and David Sidders\n\nHeaven’s Organic LLC\n\n1324 Seven Springs Boulevard, #336\n\nTrinity, FL 34655\n\nUnited States\n\ninfo@heavensorganics.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRE: 627359\n\nDate: March 28, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fheavensorganics.com\u002F on February 15, 2022, and March 9, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FHeavensOrganics\u002F, https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F, and https:\u002F\u002Ftwitter.com\u002Fheavensorganics, where you direct consumers to your website, https:\u002F\u002Fheavensorganics.com\u002F, to purchase your products. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Brand new research is showing that CBD could fight COVID-19. Check it out on Forbes” along with the image of text stating “New Study: Cannabis Compound CBD May Potentially Prevent, Fight COVID-19 Infection . . . anecdotal evidence suggests that people . . . who were prescribed regular high-potency doses of pharmaceutical-grade CBD were less likely to contract COVID . . . ‘Our research suggest that CBD . . . can block SARS-Cov-2 infection at early and even later stages of infection. . .’” [From January 25, 2022 posts on your social media websites https:\u002F\u002Fwww.facebook.com\u002FHeavensOrganics\u002F and https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F]\n\n“And in a first that shows CBD’s potential in fighting COVID-19 in people, Americans prescribed high-potency CBD oil showed lower rates of infection” [From a January 25, 2022 post on your social media website https:\u002F\u002Ftwitter.com\u002Fheavensorganics]\n\n“[H]eavensorganics #covid #covid19 #cbdhelps #cbdoil #naturesremedies #naturalremedy #natureheals” [From a January 25, 2022 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fheavensorganics\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002Fs\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002Fs\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Heaven’s Organic LLC","heavens-organic-llc-627359-03282022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fheavens-organic-llc-627359-03282022","2026-10-26T08:08:54.1347+00:00","2022-03-29","627359","Drugs","Angela Sidders and David Sidders","2026-08-20T02:04:22.665+00:00","2022-03-28",{"id":75,"raw":76,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":91,"posted_date":92,"marcs_cms_no":93,"product_type":94,"closeout_date":95,"issuing_office":80,"recipient_name":96,"body_fetched_at":97,"delivery_method":98,"recipient_title":20,"reference_number":20,"action_taken_date":99,"medical_device_id":20,"response_letter_date":20},3065,[77,78,79,80,81,13,82,13],"\u003Ctime datetime=\"2021-10-26T13:20:00Z\">10\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-13T04:00:00Z\">10\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-10132021\">Organa International Corp.\u003C\u002Fa>","Office of Human and Animal Food Operations Division West 4","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-09302024\">\u003Ctime datetime=\"2024-10-04T04:00:00Z\">10\u002F04\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Larry Mills\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Organa International Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>533 N 1650 W\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springville\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84663\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division West 4\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 13, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ref: CMS Case #613018\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mills:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.organa.net and your social media website at www.facebook.com\u002Forganainternational in June 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at the Internet address www.organa.net in June 2021 and has determined that you take orders there for your products Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Relieve Progesterone Cream, and Silver Gel. We have also reviewed your social media website, www.facebook.com\u002Forganainternational, which directs consumers to your webpage at www.organa.net to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)] in that they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Copper product page\u003C\u002Fstrong>\u003Cbr>\n• “Anemia…A copper deficiency can lead to anemia…”\u003Cbr>\n• “Heart Problems…Low intakes of copper may be associated with increased LDL ‘bad’ cholesterol and decreased HDL ‘good’ cholesterol. This may account for low copper levels being a potential contributing factor in heart and circulatory problems, which may lead to full blown heart disease.”\u003Cbr>\n• “Infections: A lack of copper in the diet may lower the body’s immune system. Normal intakes may help to reduce the risk of infection.”\u003Cbr>\n• “Osteoporosis: …[A] mild deficiency of copper may trigger, then worsen, osteoporotic lesions in bones. Boosting…intakes may help reduce the risk of osteoporosis.”\u003Cbr>\n• “Wound and Burn Treatment: …Colloidal copper promotes healing of skin burns and cuts. . .. [C]opper applied directly to the wound promotes faster healing and skin regeneration.”\u003Cbr>\n• “According to researchers…free radicals can offer a “pathway for cancer…and a variety of diseases.” Antioxidants, like those found in Colloidal copper, eliminate free radicals from the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Rhodium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “May be effective in treating HIV and cancer.”\u003Cbr>\n• “Early research has shown that rhodium has a positive effect on tumors in mice… Later research has determined that mismatched DNA is associated with carcinogenesis. Studies have shown that rhodium will bind with mismatched DNA and inhibit the damage associated with these cells.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Ruthenium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Reported to neutralize cancer cells.”\u003Cbr>\n• “Antibacterial…Studies have shown that ruthenium particles have antibacterial properties. Studies have shown that ruthenium is more effective against Gram positive and Gram negative pathogenic bacteria.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Zinc product\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Essential in wound healing.”\u003Cbr>\n• “Zinc: . . .. Essential in wound healing.”\u003Cbr>\n• “…Zinc deficiency may be contributing to the development or progression of chronic eye diseases, such as macular degeneration . . ..”\u003Cbr>\n• “[T]here is a growing body of evidence that indicates that poor zinc intake is related to…cataract formation; and optic neuritis, the inflammation of the optic nerve.”\u003Cbr>\n• “Many patients who get frequent colds and sore throats have shown a marked decrease in these outbreaks with zinc supplementation.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Uplift product page\u003C\u002Fstrong>\u003Cbr>\n• Product label:\u003Cbr>\n&nbsp; o “Uplift is a product designed to target illness. Specific colloidal minerals are added to Organa Mineral Drink to … fight viruses and bacteria.”\u003Cbr>\n&nbsp; o “Silver [an ingredient in Uplift]: A natural antibiotic\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Uplift]: Reduces the duration of colds and illnesses”\u003Cbr>\n&nbsp; o “Gold [an ingredient in Uplift]: Has anti-inflammatory properties”\u003Cbr>\n&nbsp; o “Essential Oil Blend [an ingredient in Uplift]: Antibacterial and antiviral properties…”\u003Cbr>\n• “Uplift is a product which targets the health and wellness of the body as well as the ability to fight off colds and viruses…”\u003Cbr>\n• “A special blend of pure essential oils is added [to Uplift]. These oils together all have anti-bacterial, anti-parasitic, anti-septic...properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Immune Boost product page\u003C\u002Fstrong>\u003Cbr>\n• Product label:\u003Cbr>\n&nbsp; o “Reduces Allergy Symptoms”\u003Cbr>\n• “… a tool to prevent illnesses from occurring.”\u003Cbr>\n• “sigA antibodies help by trapping bacteria before they cause harm.”\u003Cbr>\n• “When taken consistently, many have reported improvement in chronic allergy conditions, autoimmune problems...”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Essiac Tea product page\u003C\u002Fstrong>\u003Cbr>\n• Both the website and the images of your product label bear the following claims about ingredients in Essiac Tea:\u003Cbr>\n&nbsp; o “Burdock…May help reduce inflammation.”\u003Cbr>\n&nbsp; o “Slippery Elm…Soothes gastrointestinal … inflammation.”\u003Cbr>\n&nbsp; o “Turkish Rhubarb…May help reduce inflammation...”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Organa.net Gold product page\u003C\u002Fstrong>\u003Cbr>\n• “Anti-inflammatory properties: Research shows that colloidal gold can ease the swelling associated with inflammatory conditions like arthritis, bursitis, rheumatism, and tendinitis.”\u003Cbr>\n• “[G]old…may help individuals who are suffering from imbalanced emotional or mental states like anxiety, depression...”\u003Cbr>\n• “Neurological Improvements: Using colloidal gold may help improve neurological diseases in some patients, according to the Meridian Institute’s Health and Rejuvenation Research Center. The Institute followed the case of a woman with essential tremor, a neurological disorder, who found that her symptoms subsided when she took colloidal gold and came back when she stopped taking it.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Indium product page\u003C\u002Fstrong>\u003Cbr>\n• “Indium manages the vital functions that are performed by the adrenals, pituitary gland and hypothalamus. These regulate many complex functions of the body, including…perception of pain…inflammations…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Iron product page\u003C\u002Fstrong>\u003Cbr>\n• “Iron is an important component of hemoglobin, the substance in red blood cells . . .. A lack of red blood cells leads to anemia.”\u003Cbr>\n• “[I]ron is directly related to brain health and its functions. Proper flow of blood in the brain can … help to create new neural pathways to prevent cognitive disorders like dementia and Alzheimer’s disease . . ..”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Magnesium product page\u003C\u002Fstrong>\u003Cbr>\n• “[L]ack of magnesium…can result in serious deficiencies which cause illness and make you prone to infection and virus.”\u003Cbr>\n• “Blood Sugar: Magnesium allows your body to regulate blood sugar properly. Diabetes can occur when your body does not properly regulate the amount of sugar in your body.”\u003Cbr>\n• “Headaches: Magnesium has a surprisingly significant effect on migraines and headaches by helping to stop them from happening in the first place.”\u003Cbr>\n• “Depression”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Manganese product page\u003C\u002Fstrong>\u003Cbr>\n• “Although research has yet to consistently prove that manganese can prevent osteoporosis, it is believed to be one of the contributing factors that slow down the progress of that debilitating disease.”\u003Cbr>\n• “Manganese has been seen to alleviate anxiety…depression….”\u003Cbr>\n• Inflammation and Sprains: Manganese is a widely known remedy for sprains as well as inflammation as it helps in increasing the level of superoxide dismutase. . .. SOD has anti-inflammatory qualities which arthritis sufferers desperately need, so adding manganese back into the body to increase synthesis and function of SOD has been connected with a decrease in symptoms . . ..”\u003Cbr>\n• “Manganese has also exhibited efficiency in controlling the level of sugar in human blood. This may further prevent the occurrence of certain diseases like diabetes. To control the level of sugar in the blood, manganese normalizes insulin synthesis and secretion, and the unpredictable drops in blood sugar can be better regulated, providing a more normal and functional life for diabetics.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Molybdenum product page\u003C\u002Fstrong>\u003Cbr>\n• “Fights Inflammatory and Autoimmune Disease: Tetrathiomolybdate, a form of molybdenum with four sulfur atoms, lowers copper levels in the body, which makes it effective in the treatment of fibrotic, inflammatory and autoimmune diseases. . . . [I]n animal studies tetrathiomolybdate dramatically inhibits pulmonary and liver fibrosis, which is thickening and scarring of tissue, helps prevent liver damage from acetaminophen and reduces heart damage from doxorubicin, a bacterial antibiotic. Tetrathiomolybdate also shows a partially protective effect against diabetes.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Palladium product page\u003C\u002Fstrong>\u003Cbr>\n• “Palladium …is an anticoagulant…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Vanadium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Inhibits the formation of cholesterol.”\u003Cbr>\n• “Vanadium may also help in treating or preventing osteoporosis…”\u003Cbr>\n• “Diabetes: . . . One clinical trial tested the use of vanadium in treatment of diabetes and showed that vanadium had beneficial effects on patients with type 2 diabetes. Vanadium may also improve insulin sensitivity, as well as lower total and LDL, or ‘bad cholesterol,’ levels in people with type 2 diabetes . . ..”\u003Cbr>\n• “Cholesterol: Studies have shown that vanadium helps reduce the cholesterol in the liver cells and decreases blood lipid content . . .. Adequate vanadium content in the brain . . . prevents the development of sclerosis, prevents the risk of cardiovascular disease, hypertension.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net MSM (methylsulfonylmethane) product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Anti-inflammatory”\u003Cbr>\n• “Anti-inflammatory: MSM is a powerful anti-inflammatory”\u003Cbr>\n• \"Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial… Assessment of methylsulfonylmethane (MSM) on the development of osteoarthritis (OA): An animal study\".\u003Cbr>\n• “It cleans the bloodstream so allergies to food and pollens go away in about three to four days”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Relieve Progesterone Cream product page\u003C\u002Fstrong>\u003Cbr>\n• “Relieve is a combination of natural ingredients that work in harmony with the body to restore low progesterone levels. . .. Dr. John Lee of Oregon states that balancing the hormones by introducing progesterone through the skin is the first step to curbing osteoporosis. . .. Potential benefits to health: headaches\u002Fmigraines, depression, PMS prevention relief, mood swings, hot flashes, &amp; osteoporosis.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Silver Gel product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Use for skin irritations such as . . . cuts, fungus, eczema, psoriasis, and insect bites”\u003Cbr>\n• “Silver Gel aids and promotes natural healing for your skin. . .. The antimicrobial nature of silver makes Silver Gel the perfect solution for all skin irritations. . .. Try Silver Gel for: Eczema, Psoriasis, Razor Burn, Dermatitis, Rosacea, Poison Oak &amp; Ivy, Dry skin, Sunburn, Rashes, Itching, Scrapes, Sunburn, and Acne.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Blog:\u003C\u002Fstrong>\u003Cbr>\n\u003Cem>\u003Cstrong>Evaluating the Health Benefits of Colloidal Minerals, November 17, 2020\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n• “Silver has been used for centuries to treat arthritis, cancer, tuberculosis, herpes, and practically anything and everything. Even as medical science has evolved, alternative practitioners worldwide credit colloidal silver for . . . preventing or treating mild to severe infections.”\u003Cbr>\n• “Though there is no evidential proof, Colloidal Silver is thought to help the body heal itself. Other benefits can include:\u003Cbr>\n&nbsp; o “Treat herpes, flue, pneumonia, certain eye infections.”\u003Cbr>\n&nbsp; o “Treatment of cancer and AIDS”\u003Cbr>\n&nbsp; o “Healing wounds: … It is seen when wounds or ulcers are dressed with silver-containing products; the silver particles exhibit antibacterial properties. . .. [C]olloidal silver was also put through scientific test-tube experiments. These studies exhibit antiviral, antifungal, antibacterial, and anti-inflammatory properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tell Me About Zinc, December 17, 2020\u003C\u002Fstrong>\u003Cbr>\n• “Zinc…reduces the risk, severity, and duration of infectious diseases.”\u003Cbr>\n• “Zinc…is needed for natural killer cells which help fight off infections.”\u003Cbr>\n• “A zinc deficiency…causes inflammation.”\u003Cbr>\n• “There have been many articles published recently about zinc and it’s [sic] ability to raise anti-viral resistance.”\u003C\u002Fp>\n\n\u003Cp>In addition, the “Reviews” portion of your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such testimonials include:\u003Cbr>\n• Mechel Wall: “I use the nano silver, zinc and minerals daily and have stayed healthy in spite of being exposed to the current virus several times.”\u003Cbr>\n• Lila Turnbull: “I order Essiac tea from Organa after surviving Colon [sic] cancer. It was recommended from a relative whose husband had great results from it after researching its use with cancer and its prevention.”\u003Cbr>\n• Rachel Folkman: “I’ve been using Uplift for two year [sic]. . .. Anytime I start to feel sick I take a capful for a couple of days and it helps kick my sickness.”\u003Cbr>\n• Tracy Mills: “I take the mineral drink everyday along with magnesium &amp; iron. Since doing that I rarely get headaches . . ..”\u003Cbr>\n• Maribel Lopez: “[I]t has helped me for infections, pain, nausea, bleeding, for infected eyes . . ..”\u003Cbr>\n• Maria Lopez: “The colloidal silver of this company is excellent and I am recommending it to everyone I know for how well it has worked for my daughters and my grandson since [sic] for cold or throat infection, skin infection, infection of the eyes . . ..”\u003Cbr>\n• Karina: “I bought it for a friend taht [sic] is undergoing chemotherapy . She is been dringing [sic] Essiac Tea 4 months and she is toleratong [sic] the chemo treatments and her tumors have reduced and some disappeared.”\u003Cbr>\n• A. Perrone: “I had a tooth extraction scheduled because the tooth was badly decayed. 10 days before the surgery I developed an abscess at the tooth site in my palette. I knew the oral surgeon would give me antibiotics and postpone the surgery. I used…Organa 30ppm Colloidal Silver twice daily and after 5 days the abscess was gone. The extraction went off without complication.”\u003Cbr>\n• Courtlin (pertaining to your Magnesium product): “I drink the magnesium and mineral drink and it has greatly helped my gastroenteritis issues. I have been to several doctors that have never seemed to be able to diminish the pain I used to feel in my stomach but to my surprise these have helped drastically.”\u003C\u002Fp>\n\n\u003Cp>In addition, your Facebook page contains evidence of intended use of your products as drugs, including evidence in the form of personal testimonials that you posted recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such evidence of intended use includes:\u003C\u002Fp>\n\n\u003Cp>• On June 15, 2020, Organa posted the following: “Rhodium is now being heavily researched as a means to treat cancer…”\u003Cbr>\n• On February 25, 2020, Organa posted the following testimonial from “Annie”: “The Silver has worked wonderfully on cuts, burns, and bugbites [sic]. We all came down with flu symptoms but since we’re all taking silver, it’s Ben [sic] going way [sic] before it can really get started. I began drinking it as soon as I felt the tickle in my thrust [sic] and I’m almost completely better belie [sic] the week is out. I’ve bought two bottles and am ordering one today because it really works and there are no crazy side effects as opposed to pharmesutical [sic] antibiotics.”\u003Cbr>\n• On January 22, 2020, Organa posted the following testimonial from an “Organa Customer”: “I started taking Copper one week ago because of swelling in my legs and pain from a torn ligament. I was taking products for joint support but still had pain and swelling. I RESEARCHED and read that Copper pulls nutrients into ligamints [sic]. I am moving my legs up and down the stairs and bending my legs 80% better after one week! I have suffered with this for 7 years after I had back surgery. I feel this was the missing link and very thankful this product is what they say it is”\u003Cbr>\n• On January 15, 2020, Organa posted the following: “Zinc deficiency may be contributing to the development or progression of chronic eye diseases such as macular degeneration, the major cause of vision loss among older people. In one study, vision loss was reduced by 10 percent in people taking supplements…of zinc . . .. In addition, there is a growing body of evidence that indicates that poor zinc intake is related to . . . cataract formation; and optic neuritis, the inflammation of the optic nerve. Zinc is still 15% off! Head to our website now and get yourself a bottle”\u003Cbr>\n• On December 10, 2019, Organa posted the following: “Many studies have shown that a zinc deficiency can impair a large variety of immune functions and defense mechanisms in animals, and some studies have shown similar effects in humans. These effects include abnormalities and eventual shrinking of the spleen, thymus, and lymph nodes; and impaired production of antibodies-have been found to be correctable with zinc supplementation. Zinc is on sale this month! Make sure you head over to our website to get some before the sale ends!”\u003C\u002Fp>\n\n\u003Cp>Your Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Silver, Relieve Progesterone Cream, and Silver Gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application pursuant to section 505 of the FD&amp;C Act [21 U.S.C. 355] is in effect for any of these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act [21 U.S.C. 355(a) and 331(d)].\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Dietary Supplement Misbranding Charges\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your Copper, Rhodium, Ruthenium, Zinc, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, and Silver were not unapproved new drugs and\u002For misbranded drugs and described above, they would be misbranded foods under section 403 of the Act, as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 403(s)(2)(B)] in that the labels fail to identify your products using the term “dietary supplement” in accordance with 21 CFR 101.3(g), which requires that a dietary supplement be identified by the term “dietary supplement” as part of the product’s statement of identity, except the word “dietary” may be deleted and replaced by the name of the dietary ingredient in the product or an appropriate descriptive term. The product labels include a Supplements Facts label, which is evidence of your intent to market the products as Dietary Supplements.\u003C\u002Fp>\n\n\u003Cp>2. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size on the labels are incorrect. The terms “serving” or “serving size” for a dietary supplement are defined in 21 CFR 101.9(b) and 101.12, Table 2, as the maximum amount recommended on the label for consumption per eating occasion. The labels state the serving size is “1 tsp” while the directions indicate to “Take 2 tsp. once or twice daily as needed.” Furthermore, your “Silver” product is also misbranded because its label fails to include a serving size. The product labels fail to follow the listed “serving size” common measure with the equivalent metric quantity as required by 21 CFR 101.9(b)(7).\u003C\u002Fp>\n\n\u003Cp>3. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(B) [21 U.S.C. §343(q)(1)B] and 403(q)(5)(F) of the Act [21 U.S.C. §§ 343(q)(5)(F)] because the labels fail to declare the number of servings per container under the serving size on the left hand side of the nutrition label or fails to include this information as part of the net quantity of contents declaration in accordance with 21 CFR 101.36(b)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>4. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. 343 § (q)(5)(F)] in that the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products fail to enclose the nutrition information (Supplement Facts label) in a box using hairlines and titled with bolded “Supplement Facts” (not “Supplemental Facts” as incorrectly noted on your product labels) set full width, as required by 21 CFR 101.36(e)(1) and (2). Furthermore, all nutrition information within the nutrition label (Supplement Facts label) must utilize all black or one color type, as required by 21 CFR 101.36(e)(3)(ii)\u003C\u002Fp>\n\n\u003Cp>b. The labels for your “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” and “Zinc” products list iron, magnesium, manganese, molybdenum, and zinc, respectively in the nutrition information label. Iron, magnesium, manganese, molybdenum, and zinc are (b)(2)-dietary ingredients (i.e., a dietary ingredient that has a Reference Daily Intake (RDI). Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\u003C\u002Fp>\n\n\u003Cp>c. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver”, “Vanadium,” “Zinc,” and “Essiac Tea” products fail to include the subheading “Servings Per Container” as required by 21 CFR 101.36(b)(ii) and 101.36(e)(6)(i). A heavy bar must be placed beneath the subheading “Servings Per Container” except that if “Servings Per Container” is not required and, as a result, not declared, the bar must be placed beneath the subheading “Serving Size”.\u003C\u002Fp>\n\n\u003Cp>d. The labels for your “Copper,” “Gold,” “Indium,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver”, and “Essiac Tea” products fail to include a heavy bar beneath the last (b)(3)-dietary ingredient (other dietary ingredient), as required by 21 CFR 101.36(e)(6)(iii).\u003C\u002Fp>\n\n\u003Cp>e. The following product labels are misbranded in that they fail to list “Other ingredients” in a separate “Other ingredients” list outside and immediately below the Supplement Facts label in accordance with 21 CFR 101.4(g):\u003Cbr>\n\u003Cbr>\ni. The product labels for Copper and Gold list “Purified Water” within the Supplement Facts label\u003C\u002Fp>\n\n\u003Cp>ii. The product labels for Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Rhodium, Ruthenium, Vanadium, and Zinc list “Distilled Water” within the Supplement Facts\u003C\u002Fp>\n\n\u003Cp>iii. The product label for Essiac Tea lists the “Other Ingredients: Distilled Water, Potassium Sorbate, Sodium Benzoate, and Phosphoric Acid” within the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>f. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver,” and “Zinc” bear the following or similar statement: “Percent Daily Values based on a 2,000-calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\u003C\u002Fp>\n\n\u003Cp>g. Several of your product labels are for persons within more than one group. If a product is for persons within more than one group, the percent of Daily Value for each group must be presented in separate columns, as required in 21 CFR 101.36(b)(2)(iii)(E).\u003C\u002Fp>\n\n\u003Cp>h. The Essiac Tea product label lacks a declaration of % Daily Value. Furthermore, on several of your product labels the statement *“Percentage Daily Value not established” is not linked to a symbol elsewhere in the nutrition information label, as required by 21 101.36 (b)(3)(iv).\u003C\u002Fp>\n\n\u003Cp>i. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to accurately declare the net quantity of contents on the principal display panel in accordance with 21 CFR 101.7 and 15 U.S.C.§ 1453(a)(2) of the Fair Packaging and Labeling Act.\u003C\u002Fp>\n\n\u003Cp>j. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that each label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\u003C\u002Fp>\n\n\u003Cp>k. Your Essiac Tea product is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears a nutrient content claim, but the product does not meet the requirements to make such claim. Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of food must be made in accordance with a regulation authorizing the use of such a claim. Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(l)(A) of the Act. Specifically, your Essiac Tea product label bears the claim, “Slippery Elm [an ingredient in your Essiac Tea product]: Rich in . . . antioxidants,” but use of this “antioxidant” nutrient content claim fails to comply with the requirements listed in 21 CFR 101.54(g). These requirements state, in part, that for a product to bear such a claim, a reference daily intake (RDI) must have been established for each of the nutrients that are the subject of the claim [21 CFR 101.54(g)(l)], and these nutrients must have recognized antioxidant activity [21 CPR 101.54(g)(2)]. The level of each nutrient that is the subject of the claim must also be sufficient to qualify for the claim under 21 CFR 101.54(b), (c), or (e), as required by 21 CFR 101.54(g)(3). Further, nutrient content claims using the term \"antioxidant\" must include the names of the nutrients that are the subject of the claim as part of the claim or, alternatively, the term \"antioxidant\" or \"antioxidants\" may be linked by a symbol (e.g., an asterisk) that refers to the same symbol that appears elsewhere on the same panel of the product label, followed by the name or names of the nutrients with recognized antioxidant activity [21 CFR 101.54(g)(4)]. Your claim \"[r]ich in antioxidants\" is a nutrient content claim, but Essiac Tea does not meet the requirements to bear such a claim because the claim does not include the names of the nutrients that are the subject of the claim or state them on the same panel and link them with an asterisk, as required by 21 CFR 101.54(g).\u003C\u002Fp>\n\n\u003Cp>l. The Essiac product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the product label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We also offer the following comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products contain the statement, “This product is not intended to diagnose, treat, or prevent disease. Statements have not been evaluated by the FDA.” This disclaimer is not in accordance with the required text. Per 101.93, the required text should state: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Furthermore, this disclaimer is not linked to any specific structure function claim on the product label. The FDA disclaimer statement as noted on your product label must be bolded and set off in a box, and the symbol preceding the disclaimer statement must be linked to the same symbol placed at the end of each structure function statement on the label in accordance with 21 CFR 101.93(d) and (e).\u003C\u002Fp>\n\n\u003Cp>• For your product labels, there is no provision in the regulations for the listing of “Ingredients” as a heading in the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>• Your Essiac Tea product label lists the chemical preservatives sodium benzoate, potassium sorbate and phosphoric acid but does not bear labeling stating that fact, in that the label fails to include a separate description of their function as a preservative in accordance with 21 CFR 101.22(j).\u003C\u002Fp>\n\n\u003Cp>• The directions for use statements on your product labels are placed before the nutrition information. Directions for use are considered intervening material. All information appearing on the information panel must appear in one place without other intervening material, as required by 21 CFR 101.2(e).\u003C\u002Fp>\n\n\u003Cp>• The Essiac Tea product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, “Turkish rhubarb” is not a standardized common name of a botanical dietary ingredient listed in the reference Herbs of Commerce.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations Division West 4\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Even if certain of your products, such as your Indium and Palladium products, are marketed only for nonprescription indications, they would not meet the conditions under section 505G of the FD&amp;C Act [21 U.S.C. 355h] for lawful marketing without an approved application, including because indium and palladium were not active ingredients in any applicable final monograph or tentative final monograph issued under 21 CFR part 330, for purposes of section 505G(a), nor was marketing of these products permitted by an administrative order under section 505G(b). Additionally, these products would be misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)] because they would be nonprescription drugs subject to section 505G of the FD&amp;C Act that do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act [21 U.S.C. 355].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nLarry Mills\n\nRecipient Title\n\nPresident\n\nOrgana International Corp.\n\n533 N 1650 W\n\nSpringville, UT 84663\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division West 4\n\nUnited States\n\nOctober 13, 2021\n\nWARNING LETTER\n\nRef: CMS Case #613018\n\nDear Mr. Mills:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.organa.net and your social media website at www.facebook.com\u002Forganainternational in June 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website at the Internet address www.organa.net in June 2021 and has determined that you take orders there for your products Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Relieve Progesterone Cream, and Silver Gel. We have also reviewed your social media website, www.facebook.com\u002Forganainternational, which directs consumers to your webpage at www.organa.net to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)] in that they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOrgana.net Copper product page\n\n• “Anemia…A copper deficiency can lead to anemia…”\n\n• “Heart Problems…Low intakes of copper may be associated with increased LDL ‘bad’ cholesterol and decreased HDL ‘good’ cholesterol. This may account for low copper levels being a potential contributing factor in heart and circulatory problems, which may lead to full blown heart disease.”\n\n• “Infections: A lack of copper in the diet may lower the body’s immune system. Normal intakes may help to reduce the risk of infection.”\n\n• “Osteoporosis: …[A] mild deficiency of copper may trigger, then worsen, osteoporotic lesions in bones. Boosting…intakes may help reduce the risk of osteoporosis.”\n\n• “Wound and Burn Treatment: …Colloidal copper promotes healing of skin burns and cuts. . .. [C]opper applied directly to the wound promotes faster healing and skin regeneration.”\n\n• “According to researchers…free radicals can offer a “pathway for cancer…and a variety of diseases.” Antioxidants, like those found in Colloidal copper, eliminate free radicals from the body.”\n\nOrgana.net Rhodium product page\n\n• Product label: “May be effective in treating HIV and cancer.”\n\n• “Early research has shown that rhodium has a positive effect on tumors in mice… Later research has determined that mismatched DNA is associated with carcinogenesis. Studies have shown that rhodium will bind with mismatched DNA and inhibit the damage associated with these cells.”\n\nOrgana.net Ruthenium product page\n\n• Product label: “Reported to neutralize cancer cells.”\n\n• “Antibacterial…Studies have shown that ruthenium particles have antibacterial properties. Studies have shown that ruthenium is more effective against Gram positive and Gram negative pathogenic bacteria.”\n\nOrgana.net Zinc product\n\n• Product label: “Essential in wound healing.”\n\n• “Zinc: . . .. Essential in wound healing.”\n\n• “…Zinc deficiency may be contributing to the development or progression of chronic eye diseases, such as macular degeneration . . ..”\n\n• “[T]here is a growing body of evidence that indicates that poor zinc intake is related to…cataract formation; and optic neuritis, the inflammation of the optic nerve.”\n\n• “Many patients who get frequent colds and sore throats have shown a marked decrease in these outbreaks with zinc supplementation.”\n\nOrgana.net Uplift product page\n\n• Product label:\n\no “Uplift is a product designed to target illness. Specific colloidal minerals are added to Organa Mineral Drink to … fight viruses and bacteria.”\n\no “Silver [an ingredient in Uplift]: A natural antibiotic\n\no “Zinc [an ingredient in Uplift]: Reduces the duration of colds and illnesses”\n\no “Gold [an ingredient in Uplift]: Has anti-inflammatory properties”\n\no “Essential Oil Blend [an ingredient in Uplift]: Antibacterial and antiviral properties…”\n\n• “Uplift is a product which targets the health and wellness of the body as well as the ability to fight off colds and viruses…”\n\n• “A special blend of pure essential oils is added [to Uplift]. These oils together all have anti-bacterial, anti-parasitic, anti-septic...properties.”\n\nOrgana.net Immune Boost product page\n\n• Product label:\n\no “Reduces Allergy Symptoms”\n\n• “… a tool to prevent illnesses from occurring.”\n\n• “sigA antibodies help by trapping bacteria before they cause harm.”\n\n• “When taken consistently, many have reported improvement in chronic allergy conditions, autoimmune problems...”\n\nOrgana.net Essiac Tea product page\n\n• Both the website and the images of your product label bear the following claims about ingredients in Essiac Tea:\n\no “Burdock…May help reduce inflammation.”\n\no “Slippery Elm…Soothes gastrointestinal … inflammation.”\n\no “Turkish Rhubarb…May help reduce inflammation...”\n\nOrgana.net Gold product page\n\n• “Anti-inflammatory properties: Research shows that colloidal gold can ease the swelling associated with inflammatory conditions like arthritis, bursitis, rheumatism, and tendinitis.”\n\n• “[G]old…may help individuals who are suffering from imbalanced emotional or mental states like anxiety, depression...”\n\n• “Neurological Improvements: Using colloidal gold may help improve neurological diseases in some patients, according to the Meridian Institute’s Health and Rejuvenation Research Center. The Institute followed the case of a woman with essential tremor, a neurological disorder, who found that her symptoms subsided when she took colloidal gold and came back when she stopped taking it.”\n\nOrgana.net Indium product page\n\n• “Indium manages the vital functions that are performed by the adrenals, pituitary gland and hypothalamus. These regulate many complex functions of the body, including…perception of pain…inflammations…”\n\nOrgana.net Iron product page\n\n• “Iron is an important component of hemoglobin, the substance in red blood cells . . .. A lack of red blood cells leads to anemia.”\n\n• “[I]ron is directly related to brain health and its functions. Proper flow of blood in the brain can … help to create new neural pathways to prevent cognitive disorders like dementia and Alzheimer’s disease . . ..”\n\nOrgana.net Magnesium product page\n\n• “[L]ack of magnesium…can result in serious deficiencies which cause illness and make you prone to infection and virus.”\n\n• “Blood Sugar: Magnesium allows your body to regulate blood sugar properly. Diabetes can occur when your body does not properly regulate the amount of sugar in your body.”\n\n• “Headaches: Magnesium has a surprisingly significant effect on migraines and headaches by helping to stop them from happening in the first place.”\n\n• “Depression”\n\nOrgana.net Manganese product page\n\n• “Although research has yet to consistently prove that manganese can prevent osteoporosis, it is believed to be one of the contributing factors that slow down the progress of that debilitating disease.”\n\n• “Manganese has been seen to alleviate anxiety…depression….”\n\n• Inflammation and Sprains: Manganese is a widely known remedy for sprains as well as inflammation as it helps in increasing the level of superoxide dismutase. . .. SOD has anti-inflammatory qualities which arthritis sufferers desperately need, so adding manganese back into the body to increase synthesis and function of SOD has been connected with a decrease in symptoms . . ..”\n\n• “Manganese has also exhibited efficiency in controlling the level of sugar in human blood. This may further prevent the occurrence of certain diseases like diabetes. To control the level of sugar in the blood, manganese normalizes insulin synthesis and secretion, and the unpredictable drops in blood sugar can be better regulated, providing a more normal and functional life for diabetics.”\n\nOrgana.net Molybdenum product page\n\n• “Fights Inflammatory and Autoimmune Disease: Tetrathiomolybdate, a form of molybdenum with four sulfur atoms, lowers copper levels in the body, which makes it effective in the treatment of fibrotic, inflammatory and autoimmune diseases. . . . [I]n animal studies tetrathiomolybdate dramatically inhibits pulmonary and liver fibrosis, which is thickening and scarring of tissue, helps prevent liver damage from acetaminophen and reduces heart damage from doxorubicin, a bacterial antibiotic. Tetrathiomolybdate also shows a partially protective effect against diabetes.”\n\nOrgana.net Palladium product page\n\n• “Palladium …is an anticoagulant…”\n\nOrgana.net Vanadium product page\n\n• Product label: “Inhibits the formation of cholesterol.”\n\n• “Vanadium may also help in treating or preventing osteoporosis…”\n\n• “Diabetes: . . . One clinical trial tested the use of vanadium in treatment of diabetes and showed that vanadium had beneficial effects on patients with type 2 diabetes. Vanadium may also improve insulin sensitivity, as well as lower total and LDL, or ‘bad cholesterol,’ levels in people with type 2 diabetes . . ..”\n\n• “Cholesterol: Studies have shown that vanadium helps reduce the cholesterol in the liver cells and decreases blood lipid content . . .. Adequate vanadium content in the brain . . . prevents the development of sclerosis, prevents the risk of cardiovascular disease, hypertension.”\n\nOrgana.net MSM (methylsulfonylmethane) product page\n\n• Product label: “Anti-inflammatory”\n\n• “Anti-inflammatory: MSM is a powerful anti-inflammatory”\n\n• \"Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial… Assessment of methylsulfonylmethane (MSM) on the development of osteoarthritis (OA): An animal study\".\n\n• “It cleans the bloodstream so allergies to food and pollens go away in about three to four days”\n\nOrgana.net Relieve Progesterone Cream product page\n\n• “Relieve is a combination of natural ingredients that work in harmony with the body to restore low progesterone levels. . .. Dr. John Lee of Oregon states that balancing the hormones by introducing progesterone through the skin is the first step to curbing osteoporosis. . .. Potential benefits to health: headaches\u002Fmigraines, depression, PMS prevention relief, mood swings, hot flashes, & osteoporosis.”\n\nOrgana.net Silver Gel product page\n\n• Product label: “Use for skin irritations such as . . . cuts, fungus, eczema, psoriasis, and insect bites”\n\n• “Silver Gel aids and promotes natural healing for your skin. . .. The antimicrobial nature of silver makes Silver Gel the perfect solution for all skin irritations. . .. Try Silver Gel for: Eczema, Psoriasis, Razor Burn, Dermatitis, Rosacea, Poison Oak & Ivy, Dry skin, Sunburn, Rashes, Itching, Scrapes, Sunburn, and Acne.”\n\nOrgana.net Blog:\n\nEvaluating the Health Benefits of Colloidal Minerals, November 17, 2020\n\n• “Silver has been used for centuries to treat arthritis, cancer, tuberculosis, herpes, and practically anything and everything. Even as medical science has evolved, alternative practitioners worldwide credit colloidal silver for . . . preventing or treating mild to severe infections.”\n\n• “Though there is no evidential proof, Colloidal Silver is thought to help the body heal itself. Other benefits can include:\n\no “Treat herpes, flue, pneumonia, certain eye infections.”\n\no “Treatment of cancer and AIDS”\n\no “Healing wounds: … It is seen when wounds or ulcers are dressed with silver-containing products; the silver particles exhibit antibacterial properties. . .. [C]olloidal silver was also put through scientific test-tube experiments. These studies exhibit antiviral, antifungal, antibacterial, and anti-inflammatory properties.”\n\nTell Me About Zinc, December 17, 2020\n\n• “Zinc…reduces the risk, severity, and duration of infectious diseases.”\n\n• “Zinc…is needed for natural killer cells which help fight off infections.”\n\n• “A zinc deficiency…causes inflammation.”\n\n• “There have been many articles published recently about zinc and it’s [sic] ability to raise anti-viral resistance.”\n\nIn addition, the “Reviews” portion of your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such testimonials include:\n\n• Mechel Wall: “I use the nano silver, zinc and minerals daily and have stayed healthy in spite of being exposed to the current virus several times.”\n\n• Lila Turnbull: “I order Essiac tea from Organa after surviving Colon [sic] cancer. It was recommended from a relative whose husband had great results from it after researching its use with cancer and its prevention.”\n\n• Rachel Folkman: “I’ve been using Uplift for two year [sic]. . .. Anytime I start to feel sick I take a capful for a couple of days and it helps kick my sickness.”\n\n• Tracy Mills: “I take the mineral drink everyday along with magnesium & iron. Since doing that I rarely get headaches . . ..”\n\n• Maribel Lopez: “[I]t has helped me for infections, pain, nausea, bleeding, for infected eyes . . ..”\n\n• Maria Lopez: “The colloidal silver of this company is excellent and I am recommending it to everyone I know for how well it has worked for my daughters and my grandson since [sic] for cold or throat infection, skin infection, infection of the eyes . . ..”\n\n• Karina: “I bought it for a friend taht [sic] is undergoing chemotherapy . She is been dringing [sic] Essiac Tea 4 months and she is toleratong [sic] the chemo treatments and her tumors have reduced and some disappeared.”\n\n• A. Perrone: “I had a tooth extraction scheduled because the tooth was badly decayed. 10 days before the surgery I developed an abscess at the tooth site in my palette. I knew the oral surgeon would give me antibiotics and postpone the surgery. I used…Organa 30ppm Colloidal Silver twice daily and after 5 days the abscess was gone. The extraction went off without complication.”\n\n• Courtlin (pertaining to your Magnesium product): “I drink the magnesium and mineral drink and it has greatly helped my gastroenteritis issues. I have been to several doctors that have never seemed to be able to diminish the pain I used to feel in my stomach but to my surprise these have helped drastically.”\n\nIn addition, your Facebook page contains evidence of intended use of your products as drugs, including evidence in the form of personal testimonials that you posted recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such evidence of intended use includes:\n\n• On June 15, 2020, Organa posted the following: “Rhodium is now being heavily researched as a means to treat cancer…”\n\n• On February 25, 2020, Organa posted the following testimonial from “Annie”: “The Silver has worked wonderfully on cuts, burns, and bugbites [sic]. We all came down with flu symptoms but since we’re all taking silver, it’s Ben [sic] going way [sic] before it can really get started. I began drinking it as soon as I felt the tickle in my thrust [sic] and I’m almost completely better belie [sic] the week is out. I’ve bought two bottles and am ordering one today because it really works and there are no crazy side effects as opposed to pharmesutical [sic] antibiotics.”\n\n• On January 22, 2020, Organa posted the following testimonial from an “Organa Customer”: “I started taking Copper one week ago because of swelling in my legs and pain from a torn ligament. I was taking products for joint support but still had pain and swelling. I RESEARCHED and read that Copper pulls nutrients into ligamints [sic]. I am moving my legs up and down the stairs and bending my legs 80% better after one week! I have suffered with this for 7 years after I had back surgery. I feel this was the missing link and very thankful this product is what they say it is”\n\n• On January 15, 2020, Organa posted the following: “Zinc deficiency may be contributing to the development or progression of chronic eye diseases such as macular degeneration, the major cause of vision loss among older people. In one study, vision loss was reduced by 10 percent in people taking supplements…of zinc . . .. In addition, there is a growing body of evidence that indicates that poor zinc intake is related to . . . cataract formation; and optic neuritis, the inflammation of the optic nerve. Zinc is still 15% off! Head to our website now and get yourself a bottle”\n\n• On December 10, 2019, Organa posted the following: “Many studies have shown that a zinc deficiency can impair a large variety of immune functions and defense mechanisms in animals, and some studies have shown similar effects in humans. These effects include abnormalities and eventual shrinking of the spleen, thymus, and lymph nodes; and impaired production of antibodies-have been found to be correctable with zinc supplementation. Zinc is on sale this month! Make sure you head over to our website to get some before the sale ends!”\n\nYour Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Silver, Relieve Progesterone Cream, and Silver Gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here1, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application pursuant to section 505 of the FD&C Act [21 U.S.C. 355] is in effect for any of these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act [21 U.S.C. 355(a) and 331(d)].\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nDietary Supplement Misbranding Charges\n\nEven if your Copper, Rhodium, Ruthenium, Zinc, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, and Silver were not unapproved new drugs and\u002For misbranded drugs and described above, they would be misbranded foods under section 403 of the Act, as follows:\n\n1. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 403(s)(2)(B)] in that the labels fail to identify your products using the term “dietary supplement” in accordance with 21 CFR 101.3(g), which requires that a dietary supplement be identified by the term “dietary supplement” as part of the product’s statement of identity, except the word “dietary” may be deleted and replaced by the name of the dietary ingredient in the product or an appropriate descriptive term. The product labels include a Supplements Facts label, which is evidence of your intent to market the products as Dietary Supplements.\n\n2. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size on the labels are incorrect. The terms “serving” or “serving size” for a dietary supplement are defined in 21 CFR 101.9(b) and 101.12, Table 2, as the maximum amount recommended on the label for consumption per eating occasion. The labels state the serving size is “1 tsp” while the directions indicate to “Take 2 tsp. once or twice daily as needed.” Furthermore, your “Silver” product is also misbranded because its label fails to include a serving size. The product labels fail to follow the listed “serving size” common measure with the equivalent metric quantity as required by 21 CFR 101.9(b)(7).\n\n3. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(B) [21 U.S.C. §343(q)(1)B] and 403(q)(5)(F) of the Act [21 U.S.C. §§ 343(q)(5)(F)] because the labels fail to declare the number of servings per container under the serving size on the left hand side of the nutrition label or fails to include this information as part of the net quantity of contents declaration in accordance with 21 CFR 101.36(b)(1)(ii).\n\n4. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. 343 § (q)(5)(F)] in that the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36. For example:\n\na. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products fail to enclose the nutrition information (Supplement Facts label) in a box using hairlines and titled with bolded “Supplement Facts” (not “Supplemental Facts” as incorrectly noted on your product labels) set full width, as required by 21 CFR 101.36(e)(1) and (2). Furthermore, all nutrition information within the nutrition label (Supplement Facts label) must utilize all black or one color type, as required by 21 CFR 101.36(e)(3)(ii)\n\nb. The labels for your “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” and “Zinc” products list iron, magnesium, manganese, molybdenum, and zinc, respectively in the nutrition information label. Iron, magnesium, manganese, molybdenum, and zinc are (b)(2)-dietary ingredients (i.e., a dietary ingredient that has a Reference Daily Intake (RDI). Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\n\nc. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver”, “Vanadium,” “Zinc,” and “Essiac Tea” products fail to include the subheading “Servings Per Container” as required by 21 CFR 101.36(b)(ii) and 101.36(e)(6)(i). A heavy bar must be placed beneath the subheading “Servings Per Container” except that if “Servings Per Container” is not required and, as a result, not declared, the bar must be placed beneath the subheading “Serving Size”.\n\nd. The labels for your “Copper,” “Gold,” “Indium,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver”, and “Essiac Tea” products fail to include a heavy bar beneath the last (b)(3)-dietary ingredient (other dietary ingredient), as required by 21 CFR 101.36(e)(6)(iii).\n\ne. The following product labels are misbranded in that they fail to list “Other ingredients” in a separate “Other ingredients” list outside and immediately below the Supplement Facts label in accordance with 21 CFR 101.4(g):\n\ni. The product labels for Copper and Gold list “Purified Water” within the Supplement Facts label\n\nii. The product labels for Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Rhodium, Ruthenium, Vanadium, and Zinc list “Distilled Water” within the Supplement Facts\n\niii. The product label for Essiac Tea lists the “Other Ingredients: Distilled Water, Potassium Sorbate, Sodium Benzoate, and Phosphoric Acid” within the Supplement Facts label.\n\nf. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver,” and “Zinc” bear the following or similar statement: “Percent Daily Values based on a 2,000-calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\n\ng. Several of your product labels are for persons within more than one group. If a product is for persons within more than one group, the percent of Daily Value for each group must be presented in separate columns, as required in 21 CFR 101.36(b)(2)(iii)(E).\n\nh. The Essiac Tea product label lacks a declaration of % Daily Value. Furthermore, on several of your product labels the statement *“Percentage Daily Value not established” is not linked to a symbol elsewhere in the nutrition information label, as required by 21 101.36 (b)(3)(iv).\n\ni. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to accurately declare the net quantity of contents on the principal display panel in accordance with 21 CFR 101.7 and 15 U.S.C.§ 1453(a)(2) of the Fair Packaging and Labeling Act.\n\nj. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that each label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\n\nk. Your Essiac Tea product is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears a nutrient content claim, but the product does not meet the requirements to make such claim. Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of food must be made in accordance with a regulation authorizing the use of such a claim. Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(l)(A) of the Act. Specifically, your Essiac Tea product label bears the claim, “Slippery Elm [an ingredient in your Essiac Tea product]: Rich in . . . antioxidants,” but use of this “antioxidant” nutrient content claim fails to comply with the requirements listed in 21 CFR 101.54(g). These requirements state, in part, that for a product to bear such a claim, a reference daily intake (RDI) must have been established for each of the nutrients that are the subject of the claim [21 CFR 101.54(g)(l)], and these nutrients must have recognized antioxidant activity [21 CPR 101.54(g)(2)]. The level of each nutrient that is the subject of the claim must also be sufficient to qualify for the claim under 21 CFR 101.54(b), (c), or (e), as required by 21 CFR 101.54(g)(3). Further, nutrient content claims using the term \"antioxidant\" must include the names of the nutrients that are the subject of the claim as part of the claim or, alternatively, the term \"antioxidant\" or \"antioxidants\" may be linked by a symbol (e.g., an asterisk) that refers to the same symbol that appears elsewhere on the same panel of the product label, followed by the name or names of the nutrients with recognized antioxidant activity [21 CFR 101.54(g)(4)]. Your claim \"[r]ich in antioxidants\" is a nutrient content claim, but Essiac Tea does not meet the requirements to bear such a claim because the claim does not include the names of the nutrients that are the subject of the claim or state them on the same panel and link them with an asterisk, as required by 21 CFR 101.54(g).\n\nl. The Essiac product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the product label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction.\n\nWe also offer the following comments:\n\n• Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products contain the statement, “This product is not intended to diagnose, treat, or prevent disease. Statements have not been evaluated by the FDA.” This disclaimer is not in accordance with the required text. Per 101.93, the required text should state: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Furthermore, this disclaimer is not linked to any specific structure function claim on the product label. The FDA disclaimer statement as noted on your product label must be bolded and set off in a box, and the symbol preceding the disclaimer statement must be linked to the same symbol placed at the end of each structure function statement on the label in accordance with 21 CFR 101.93(d) and (e).\n\n• For your product labels, there is no provision in the regulations for the listing of “Ingredients” as a heading in the Supplement Facts label.\n\n• Your Essiac Tea product label lists the chemical preservatives sodium benzoate, potassium sorbate and phosphoric acid but does not bear labeling stating that fact, in that the label fails to include a separate description of their function as a preservative in accordance with 21 CFR 101.22(j).\n\n• The directions for use statements on your product labels are placed before the nutrition information. Directions for use are considered intervening material. All information appearing on the information panel must appear in one place without other intervening material, as required by 21 CFR 101.2(e).\n\n• The Essiac Tea product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, “Turkish rhubarb” is not a standardized common name of a botanical dietary ingredient listed in the reference Herbs of Commerce.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations Division West 4\n\n________________________\n\n1 Even if certain of your products, such as your Indium and Palladium products, are marketed only for nonprescription indications, they would not meet the conditions under section 505G of the FD&C Act [21 U.S.C. 355h] for lawful marketing without an approved application, including because indium and palladium were not active ingredients in any applicable final monograph or tentative final monograph issued under 21 CFR part 330, for purposes of section 505G(a), nor was marketing of these products permitted by an administrative order under section 505G(b). Additionally, these products would be misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)] because they would be nonprescription drugs subject to section 505G of the FD&C Act that do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act [21 U.S.C. 355].","Organa International Corp.","organa-international-corp-613018-10132021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-10132021","2026-10-26T08:09:39.061065+00:00","Closed Out","2021-10-26","613018","DrugsFood & Beverages","2024-10-04","Larry Mills","2026-08-20T02:29:50.189+00:00","VIA UPS","2021-10-13",{"id":101,"raw":102,"subject":107,"body_html":108,"body_text":109,"firm_name":110,"letter_id":111,"created_at":112,"fei_number":20,"letter_url":113,"updated_at":114,"action_type":23,"case_status":24,"posted_date":115,"marcs_cms_no":116,"product_type":117,"closeout_date":20,"issuing_office":106,"recipient_name":118,"body_fetched_at":119,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":120,"medical_device_id":20,"response_letter_date":20},57,[103,104,105,106,107,13,13,13],"\u003Ctime datetime=\"2026-07-07T04:00:00Z\">07\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbushman-organic-farms-inc-729451-05142026\">Bushman Organic Farms, Inc.\u003C\u002Fa>","Human Foods Program","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Todd J. Bushman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bushman Organic Farms, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1402 Highway 150\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Calmar\u003C\u002Fspan>, \u003Cspan>IA\u003C\u002Fspan> \u003Cspan>52132-7608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>05\u002F14\u002F2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 729451\u003C\u002Fp>\u003Cp>Dear Mr. Todd J. Bushman\u003C\u002Fp>\u003Cp>On August 15 – September 27, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Bushman Organic Farms, Inc. located at 1402 Highway 150 Calmar, IA 52132-7608. We also conducted an inspection on March 17 – March 27, 2026. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on March 27, 2026.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Organic soybean meal imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Brian Erickson, Compliance Officer, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Brian Erickson via email at brian.erickson@fda.hhs.gov. Please reference CMS # 729451 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Todd Cato\u003Cbr>Program Division Director\u003Cbr>Division of Southwest Imports\u003Cbr>One Main Place\u003Cbr>1201 Main Street, Suite 7200\u003Cbr>Dallas, TX 75202\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTodd J. Bushman\n\nRecipient Title\n\nCEO\n\nBushman Organic Farms, Inc.\n\n1402 Highway 150\n\nCalmar, IA 52132-7608\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\n05\u002F14\u002F2026\nWARNING LETTER\nRe: CMS # 729451\nDear Mr. Todd J. Bushman\nOn August 15 – September 27, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Bushman Organic Farms, Inc. located at 1402 Highway 150 Calmar, IA 52132-7608. We also conducted an inspection on March 17 – March 27, 2026. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on March 27, 2026.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nOrganic soybean meal imported from (b)(4), located in (b)(4)\nOrganic soybean meal imported from (b)(4), located in (b)(4)\nOrganic soybean meal imported from (b)(4), located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nOrganic soybean meal imported from (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n(b)(3)(A)\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n(b)(3)(A)\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Brian Erickson, Compliance Officer, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Brian Erickson via email at brian.erickson@fda.hhs.gov. Please reference CMS # 729451 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nTodd Cato\nProgram Division Director\nDivision of Southwest Imports\nOne Main Place\n1201 Main Street, Suite 7200\nDallas, TX 75202","Bushman Organic Farms, Inc.","bushman-organic-farms-inc-729451-05142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbushman-organic-farms-inc-729451-05142026","2026-10-26T08:08:09.491211+00:00","2026-07-07","729451","Food & Beverages","Todd J. Bushman","2026-08-19T04:30:43.876+00:00","2026-05-14",{"id":122,"raw":123,"subject":128,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":133,"fei_number":20,"letter_url":134,"updated_at":135,"action_type":23,"case_status":24,"posted_date":136,"marcs_cms_no":137,"product_type":117,"closeout_date":20,"issuing_office":127,"recipient_name":138,"body_fetched_at":139,"delivery_method":140,"recipient_title":20,"reference_number":20,"action_taken_date":141,"medical_device_id":20,"response_letter_date":20},1330,[124,125,126,127,128,13,13,13],"\u003Ctime datetime=\"2024-08-06T13:20:00Z\">08\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-08T04:00:00Z\">07\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigh-quality-organics-inc-677503-07082024\">High Quality Organics, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Boligala C. Raju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>High Quality Organics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12101 Moya Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Reno\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89506-2600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 8, 2024\u003C\u002Fp>\n\n\u003Cp>WL CMS# 677503\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Raju:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) spice facility, located at 12101 Moya Blvd., Reno, NV, from November 27 through December 07, 2023, and January 03 through January 04, 2024. The inspection covered processing and\u002For packaging of RTE organic herbs, spices, dried fruit and peels, and dried vegetables. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE herbs, spices, dried fruit and peels, and dried vegetables processed and\u002For packaged in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations. You provided a written response to the inspectional findings on January 25, 2024, describing corrective actions taken by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Supply-Chain Program (21 CFR Part 117, Subpart G)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not implement a risk-based supply-chain program for those raw materials and ingredients for which you have identified a hazard requiring a supply-chain-applied control, as required per 21 CFR 117.405(a)(1). Specifically, your written supply-chain program does not provide assurance that a hazard requiring a supply-chain-applied control has been significantly minimized or prevented, as required per 21 CFR 117.410(c). You receive untreated herbs, spices, dried fruits and peels, and dried vegetable products. You direct the untreated products to \u003Cstrong>(b)(4)\u003C\u002Fstrong> third-party providers that apply&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated during the inspection that you manage your third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers through your supply-chain program, and you expect \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers to treat your products with validated parameters that will provide a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction for \u003Cem>Salmonella\u003C\u002Fem>. Per your Hazard Analysis &amp; Preventive Controls Determination record at step “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” the preventive control measure is “Validated lethality ‘kill step’ with Treatment Certificate”. However, your supply-chain program does not verify that the parameters selected and applied by your \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers are adequate to control the hazard of vegetative pathogens such as \u003Cem>Salmonella\u003C\u002Fem>. You do not review the process parameters identified in the treatment certificate from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, as identified as a preventive control measure required by your Hazard Analysis, and you have not comprehensively evaluated whether the parameters are appropriate for all your products undergoing the treatment. You do not maintain documentation that the untreated spices you purchase and send to the third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;providers are treated under a validated process that delivers an appropriate destruction of \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>As examples:\u003C\u002Fp>\n\n\u003Cp>a. On March 30, 2023, you sent \u003Cstrong>(b)(4)\u003C\u002Fstrong> of Organic Caraway Seeds to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for treatment. You received a \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certificate dated April 7, 2023, that stated the caraway seeds were processed at a temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and “[t]he temperature was held for the duration at the core of the product.” You have not verified that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella. The third-party audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated, “treatment validations will occur upon request of the customer”. You have not requested a validation study to support the process parameters listed on the caraway seeds \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificate. Specifically, during the inspection you told our investigator that you have not reviewed validation studies, as they are proprietary to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, and you do not maintain documentation that assures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process delivers a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction. The third-party audit report also stated (under review of the Food Safety Plan at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step), “No pathogens were identified since this is just a customer treatment (toll processing) with no validation [by HQO]. This is disclosed to service customers vis contracts or WO.” The caraway seeds at issue were used in the processing of O Montreal a.k.a. Nebbraska Stk, lot # 65443. You have four validation studies conducted prior to 2017 for black peppercorn, sliced ginger, parsley and crushed red pepper – all of which listed critical parameters with higher time and\u002For temperatures than what is listed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificate.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is working with their technical department to determine the best way to address this concern. However, your response did not demonstrate that all products sent to third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers will be treated with appropriate parameters to control \u003Cem>Salmonella\u003C\u002Fem>. You did not include a revised procedure for your supply-chain program or revised implementation records. You did not indicate that you will ensure the provider validated its treatment, you will review this validation information, or you will verify the validation appropriately applies to each type of product sent to this provider.\u003C\u002Fp>\n\n\u003Cp>Also, you have previously promised to take corrective actions. At the conclusion of the FDA 2020 inspection, an FDA-483 was issued to you on December 4, 2020, for failure to identify a preventive control for pathogens in your RTE dried herbs and spices and for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw materials which you sent to a third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> facility; you did not verify that validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes were in place. You stated in your response, dated December 24, 2020, that all products would be treated with a validated lethality process by either your supplier or contracted third-party facility. You also stated, “Documentation on the validated lethality treatment must be reviewed by HQO prior to shipment of product to ensure that the supplier has a validated lethality treatment for the particular product and size\u002Fshape that is to be shipped for treatment.” This review was not conducted.\u003C\u002Fp>\n\n\u003Cp>b. On September 6, 2023, you sent \u003Cstrong>(b)(4)\u003C\u002Fstrong> of dried Organic Lemon Peel to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for treatment. You received a certificate of treatment that same day that stated the “Minimum Temperature &amp; Dwell Time: \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The third-party audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated the critical limit for the treatment is \u003Cstrong>(b)(4)\u003C\u002Fstrong>”, but product and customer specific. You did not verify that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been validated to provide an appropriate logarithmic reduction for pathogens such as \u003Cem>Salmonella\u003C\u002Fem> or how it is applicable to each type of product you send for treatment. During the inspection, you told our investigator that you have not reviewed validation studies, as they are proprietary to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, and that you do not maintain documentation that assures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process delivers a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction. The lemon peel was used in the manufacturing of Organic No Salt Blend, lot # 65724.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> revised the language on its treatment certificate to include the statement: “The treatment process follow \u003Cem>[sic]\u003C\u002Fem> our ’\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ by subjecting the product to our \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>of pathogens (Salmonella) that follow specific treatment parameters which are product specific.” However, your response did not demonstrate that all products will be treated with appropriate parameters to control \u003Cem>Salmonella\u003C\u002Fem>. You did not indicate that you will review the validation information relied on by the provider to ensure the treatment is adequate. You did not indicate that you will verify the validation appropriately applies to each type of product sent to this provider.\u003C\u002Fp>\n\n\u003Cp>Also, your written supply chain program procedure entitled “VENDOR MANAGEMENT PROGRAM, Revision Date: 06\u002F12\u002F2023” states, under “Vendor Monitoring”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Per the procedure, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to assist with ongoing monitoring to ensure vendor compliance. On December 4, 2023, our investigator requested to review the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your suppliers who provided raw materials used in the manufacturing of No Salt Blend. You were unable to provide a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for one of the suppliers. Furthermore, you indicated that you stopped completing \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all your suppliers after June 2021 despite still receiving raw materials from some suppliers since that date. Also, \u003Cstrong>(b)(4)\u003C\u002Fstrong> completed up until then and reviewed during the inspection were incomplete to ensure adequate supply-chain control. For example, the supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which supplied Organic Vegmix containing carrot, garlic, onion, red bell pepper, and tomato granules) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which supplied organic cumin) dated June 4, 2021 were incomplete in that you did not record what valid documents you had on file, what documents were missing (e.g., current third-party audit results or validation studies), and what requests were pending. These ingredients were used in the processing of No Salt Blend, lot # 65724.\u003C\u002Fp>\n\n\u003Cp>You explained in your written response that the existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for documenting supplier reviews was not maintained due to employee attrition and the realignment of resources. Further, you stated a more sustainable revised system to document supplier compliance and performance in your supply-chain is being developed and it will be utilized \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your decision process to maintain or discontinue approval of a supplier. However, you have previously promised to take corrective actions. At the conclusion of the FDA 2021 inspection, the FDA-483 dated September 17, 2021, included an observation that you did not conduct and document appropriate supplier verification activities such as onsite audits for the control of the pathogen and recontamination with environmental pathogens hazards through the supply-chain. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers given as an example for this observation. Further, it was noted in the 2021 inspection report that you did not have complete supplier documentation per the Vendor Management Program in place at the time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In your response received on October 8, 2021, you explained you developed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and began a pilot program in April 2021 which you expanded to include all suppliers in October 2021. Further, you promised to implement and maintain this “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” system to ensure maintenance of required records. Your response did not include evidence to demonstrate the system had been implemented per your description of its capabilities. We are concerned that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system may not be attainable as you failed to provide evidence or explanation of how it will be different from your previous \u003Cstrong>(b)(4)\u003C\u002Fstrong> system developed in response to the 2021 Inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2. You did not conduct a reanalysis of your food safety plan when needed, as required by 21 CFR 117.170. You must conduct a reanalysis of the food safety plan as a whole, or the applicable portion of the food safety plan, whenever you became aware of new information about potential hazards associated with the food, as required per 21 CFR 117.170(b)(2). Specifically, on April 28, 2023, you became aware of new information when you received a complaint from your customer that Ground Organic Parsley, lot # 62868 and lot # 63196, tested positive for the pesticide Chlorpyrifos (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). There is no tolerance for Chlorpyrifos in parsley; therefore, the parsley lots are adulterated within the meaning of section 402(a)(2)(B) of the Act [21 U.S.C. § 342(a)(2)(B)], in that they bear or contain a pesticide chemical residue that is unsafe within the meaning of section 408(a) of the Act [21 U.S.C. § 346 (a)].\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigator discussed with you that pesticides was not identified in your hazard analysis as a hazard requiring a supply-chain control. Your hazard analysis includes a justification of “only using organic suppliers with \u003Cstrong>(b)(4)\u003C\u002Fstrong> crop testing for pesticides”. Considering the complaint from April 2023, a reanalysis of the pesticide hazard is warranted to consider whether pesticides are a hazard requiring a supply-chain-applied control.\u003C\u002Fp>\n\n\u003Cp>In your written response you included a statement, in relation to unidentified hazards, that your Food Safety Team will review your current Food Safety Plan and make necessary changes. However, you did not provide evidence of review and revision or a timeframe for review and revision of your Food Safety Plan.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We also offer the following comment:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that in your supply-chain procedure “VENDOR MANAGEMENT PROGRAM Revision Date: 06\u002F12\u002F2023”, as a “Minimum Requirement for All Approved Vendors”, you identified a supplier verification activity of an \u003Cstrong>(b)(4)\u003C\u002Fstrong> onsite audit for GMPs and food safety. Furthermore, you stated that copies of third-party audit results are reviewed for passing score, corrective actions to observations, processing procedures, sanitation, traffic flow, GMP programs, and environmental monitoring. However, your written response acknowledged that you do not consistently document your review of third-party audit results. For the supplier verification activity of an onsite audit, you must review the audit results and document that review in order to ensure supply-chain-applied control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response to this letter should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS# 677503 when replying.\u003C\u002Fp>\n\n\u003Cp>If you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Boligala C. Raju\n\nRecipient Title\n\nChief Executive Officer\n\nHigh Quality Organics, Inc.\n\n12101 Moya Blvd.\n\nReno, NV 89506-2600\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nJuly 8, 2024\n\nWL CMS# 677503\n\nDear Mr. Raju:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) spice facility, located at 12101 Moya Blvd., Reno, NV, from November 27 through December 07, 2023, and January 03 through January 04, 2024. The inspection covered processing and\u002For packaging of RTE organic herbs, spices, dried fruit and peels, and dried vegetables. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on FDA’s inspectional findings, we have determined that the RTE herbs, spices, dried fruit and peels, and dried vegetables processed and\u002For packaged in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA’s homepage at www.fda.gov.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations. You provided a written response to the inspectional findings on January 25, 2024, describing corrective actions taken by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\n\nYour significant violations are as follows:\n\nSupply-Chain Program (21 CFR Part 117, Subpart G)\n\n1. You did not implement a risk-based supply-chain program for those raw materials and ingredients for which you have identified a hazard requiring a supply-chain-applied control, as required per 21 CFR 117.405(a)(1). Specifically, your written supply-chain program does not provide assurance that a hazard requiring a supply-chain-applied control has been significantly minimized or prevented, as required per 21 CFR 117.410(c). You receive untreated herbs, spices, dried fruits and peels, and dried vegetable products. You direct the untreated products to (b)(4) third-party providers that apply (b)(4). You stated during the inspection that you manage your third-party (b)(4) providers through your supply-chain program, and you expect (b)(4) providers to treat your products with validated parameters that will provide a (b)(4) reduction for Salmonella. Per your Hazard Analysis & Preventive Controls Determination record at step “(b)(4),” the preventive control measure is “Validated lethality ‘kill step’ with Treatment Certificate”. However, your supply-chain program does not verify that the parameters selected and applied by your (b)(4) providers are adequate to control the hazard of vegetative pathogens such as Salmonella. You do not review the process parameters identified in the treatment certificate from the (b)(4) providers, as identified as a preventive control measure required by your Hazard Analysis, and you have not comprehensively evaluated whether the parameters are appropriate for all your products undergoing the treatment. You do not maintain documentation that the untreated spices you purchase and send to the third-party (b)(4) providers are treated under a validated process that delivers an appropriate destruction of Salmonella.\n\nAs examples:\n\na. On March 30, 2023, you sent (b)(4) of Organic Caraway Seeds to (b)(4) for treatment. You received a (b)(4) Certificate dated April 7, 2023, that stated the caraway seeds were processed at a temperature of (b)(4) and “[t]he temperature was held for the duration at the core of the product.” You have not verified that this (b)(4) has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella. The third-party audit report for (b)(4) stated, “treatment validations will occur upon request of the customer”. You have not requested a validation study to support the process parameters listed on the caraway seeds (b)(4) certificate. Specifically, during the inspection you told our investigator that you have not reviewed validation studies, as they are proprietary to the (b)(4) providers, and you do not maintain documentation that assures the (b)(4) process delivers a (b)(4) reduction. The third-party audit report also stated (under review of the Food Safety Plan at the (b)(4) step), “No pathogens were identified since this is just a customer treatment (toll processing) with no validation [by HQO]. This is disclosed to service customers vis contracts or WO.” The caraway seeds at issue were used in the processing of O Montreal a.k.a. Nebbraska Stk, lot # 65443. You have four validation studies conducted prior to 2017 for black peppercorn, sliced ginger, parsley and crushed red pepper – all of which listed critical parameters with higher time and\u002For temperatures than what is listed on the (b)(4) certificate.\n\nIn your written response, you stated that (b)(4) is working with their technical department to determine the best way to address this concern. However, your response did not demonstrate that all products sent to third-party (b)(4) providers will be treated with appropriate parameters to control Salmonella. You did not include a revised procedure for your supply-chain program or revised implementation records. You did not indicate that you will ensure the provider validated its treatment, you will review this validation information, or you will verify the validation appropriately applies to each type of product sent to this provider.\n\nAlso, you have previously promised to take corrective actions. At the conclusion of the FDA 2020 inspection, an FDA-483 was issued to you on December 4, 2020, for failure to identify a preventive control for pathogens in your RTE dried herbs and spices and for the (b)(4) raw materials which you sent to a third-party (b)(4) facility; you did not verify that validated (b)(4) processes were in place. You stated in your response, dated December 24, 2020, that all products would be treated with a validated lethality process by either your supplier or contracted third-party facility. You also stated, “Documentation on the validated lethality treatment must be reviewed by HQO prior to shipment of product to ensure that the supplier has a validated lethality treatment for the particular product and size\u002Fshape that is to be shipped for treatment.” This review was not conducted.\n\nb. On September 6, 2023, you sent (b)(4) of dried Organic Lemon Peel to (b)(4) for treatment. You received a certificate of treatment that same day that stated the “Minimum Temperature & Dwell Time: (b)(4).” The third-party audit report for (b)(4) stated the critical limit for the treatment is (b)(4)”, but product and customer specific. You did not verify that this (b)(4) has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella or how it is applicable to each type of product you send for treatment. During the inspection, you told our investigator that you have not reviewed validation studies, as they are proprietary to the (b)(4) providers, and that you do not maintain documentation that assures the (b)(4) process delivers a (b)(4) reduction. The lemon peel was used in the manufacturing of Organic No Salt Blend, lot # 65724.\n\nIn your written response, you stated that (b)(4) revised the language on its treatment certificate to include the statement: “The treatment process follow [sic] our ’(b)(4)’ by subjecting the product to our (b)(4) of pathogens (Salmonella) that follow specific treatment parameters which are product specific.” However, your response did not demonstrate that all products will be treated with appropriate parameters to control Salmonella. You did not indicate that you will review the validation information relied on by the provider to ensure the treatment is adequate. You did not indicate that you will verify the validation appropriately applies to each type of product sent to this provider.\n\nAlso, your written supply chain program procedure entitled “VENDOR MANAGEMENT PROGRAM, Revision Date: 06\u002F12\u002F2023” states, under “Vendor Monitoring”, “(b)(4).” Per the procedure, “(b)(4)” to assist with ongoing monitoring to ensure vendor compliance. On December 4, 2023, our investigator requested to review the (b)(4) for (b)(4) of your suppliers who provided raw materials used in the manufacturing of No Salt Blend. You were unable to provide a (b)(4) for one of the suppliers. Furthermore, you indicated that you stopped completing (b)(4) for all your suppliers after June 2021 despite still receiving raw materials from some suppliers since that date. Also, (b)(4) completed up until then and reviewed during the inspection were incomplete to ensure adequate supply-chain control. For example, the supplier (b)(4) for (b)(4) (which supplied Organic Vegmix containing carrot, garlic, onion, red bell pepper, and tomato granules) and (b)(4) (which supplied organic cumin) dated June 4, 2021 were incomplete in that you did not record what valid documents you had on file, what documents were missing (e.g., current third-party audit results or validation studies), and what requests were pending. These ingredients were used in the processing of No Salt Blend, lot # 65724.\n\nYou explained in your written response that the existing (b)(4) system for documenting supplier reviews was not maintained due to employee attrition and the realignment of resources. Further, you stated a more sustainable revised system to document supplier compliance and performance in your supply-chain is being developed and it will be utilized (b)(4) in your decision process to maintain or discontinue approval of a supplier. However, you have previously promised to take corrective actions. At the conclusion of the FDA 2021 inspection, the FDA-483 dated September 17, 2021, included an observation that you did not conduct and document appropriate supplier verification activities such as onsite audits for the control of the pathogen and recontamination with environmental pathogens hazards through the supply-chain. (b)(4) was (b)(4) suppliers given as an example for this observation. Further, it was noted in the 2021 inspection report that you did not have complete supplier documentation per the Vendor Management Program in place at the time for (b)(4). In your response received on October 8, 2021, you explained you developed a (b)(4) system and began a pilot program in April 2021 which you expanded to include all suppliers in October 2021. Further, you promised to implement and maintain this “(b)(4)” system to ensure maintenance of required records. Your response did not include evidence to demonstrate the system had been implemented per your description of its capabilities. We are concerned that your (b)(4) system may not be attainable as you failed to provide evidence or explanation of how it will be different from your previous (b)(4) system developed in response to the 2021 Inspection.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n\n2. You did not conduct a reanalysis of your food safety plan when needed, as required by 21 CFR 117.170. You must conduct a reanalysis of the food safety plan as a whole, or the applicable portion of the food safety plan, whenever you became aware of new information about potential hazards associated with the food, as required per 21 CFR 117.170(b)(2). Specifically, on April 28, 2023, you became aware of new information when you received a complaint from your customer that Ground Organic Parsley, lot # 62868 and lot # 63196, tested positive for the pesticide Chlorpyrifos ((b)(4)). There is no tolerance for Chlorpyrifos in parsley; therefore, the parsley lots are adulterated within the meaning of section 402(a)(2)(B) of the Act [21 U.S.C. § 342(a)(2)(B)], in that they bear or contain a pesticide chemical residue that is unsafe within the meaning of section 408(a) of the Act [21 U.S.C. § 346 (a)].\n\nDuring the inspection, our investigator discussed with you that pesticides was not identified in your hazard analysis as a hazard requiring a supply-chain control. Your hazard analysis includes a justification of “only using organic suppliers with (b)(4) crop testing for pesticides”. Considering the complaint from April 2023, a reanalysis of the pesticide hazard is warranted to consider whether pesticides are a hazard requiring a supply-chain-applied control.\n\nIn your written response you included a statement, in relation to unidentified hazards, that your Food Safety Team will review your current Food Safety Plan and make necessary changes. However, you did not provide evidence of review and revision or a timeframe for review and revision of your Food Safety Plan.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nWe also offer the following comment:\n\nWe note that in your supply-chain procedure “VENDOR MANAGEMENT PROGRAM Revision Date: 06\u002F12\u002F2023”, as a “Minimum Requirement for All Approved Vendors”, you identified a supplier verification activity of an (b)(4) onsite audit for GMPs and food safety. Furthermore, you stated that copies of third-party audit results are reviewed for passing score, corrective actions to observations, processing procedures, sanitation, traffic flow, GMP programs, and environmental monitoring. However, your written response acknowledged that you do not consistently document your review of third-party audit results. For the supplier verification activity of an onsite audit, you must review the audit results and document that review in order to ensure supply-chain-applied control.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response to this letter should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number CMS# 677503 when replying.\n\nIf you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","High Quality Organics, Inc.","high-quality-organics-inc-677503-07082024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigh-quality-organics-inc-677503-07082024","2026-10-26T08:08:54.858284+00:00","2024-08-06","677503","Mr. Boligala C. Raju","2026-08-19T23:54:29.897+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-07-08",{"id":143,"raw":144,"subject":149,"body_html":150,"body_text":151,"firm_name":152,"letter_id":153,"created_at":154,"fei_number":20,"letter_url":155,"updated_at":156,"action_type":23,"case_status":24,"posted_date":157,"marcs_cms_no":158,"product_type":94,"closeout_date":20,"issuing_office":148,"recipient_name":159,"body_fetched_at":160,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":161,"medical_device_id":20,"response_letter_date":20},2223,[145,146,147,148,149,13,13,13],"\u003Ctime datetime=\"2023-01-31T14:59:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-30T05:00:00Z\">01\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganic-heirloom-plants-643997-01302023\">Organic Heirloom Plants\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wendy Wiegert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Organic Heirloom Plants\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>51594 Boston Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hancock\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49930\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@organicheirloomplants.com\"> info@organicheirloomplants.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:organicheirloomplants@yahoo.com\"> organicheirloomplants@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: CMS # 643997\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Wiegert:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Forganicheirloomplants.com in October 2022. We also reviewed your promotional literature that accompanies your products and your social media website at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies, where you direct consumers to your website, https:\u002F\u002Forganicheirloomplants.com, to purchase your products Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Ivermectwin, Nature’s Ancer, Zeolite, and Chaga Mushroom. Based on our review, the claims on your websites and promotional literature establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Act, 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the Act, 21 U.S.C. § 352. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>The Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving mpox.\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking measures to protect customers from products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure mpox. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure mpox in people. We request that you cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of mpox.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Sarracenia Purpurea\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Sarracenia Purpurea at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fmonkey-pox-sarracenia-purpurea-herbal-natural-remedy-herbal-tincture:\u003Cbr>\n• “Monkey Pox, Sarracenia Purpurea, Herbal Natural Remedy”\u003Cbr>\n• “For decades, research has shown the effectiveness of Sarracenia Purpurea (Pitcher Plant) against past outbreaks of small pox [sic] in the 19th Century, found to halt viral replication in viral, derived from the Variola Virus also associated with Monkey Pox.”\u003C\u002Fp>\n\n\u003Cp>The above noted claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Forganicheirloomplants.com through Internet searches. The metatags include:\u003Cbr>\n• “Monkey Pox, Sarracenia Purpurea, Herbal Natural Remedy”\u003C\u002Fp>\n\n\u003Cp>On your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies:\u003Cbr>\n• In a May 30, 2022, post: “Harvesting Pitcher Plant [another name for Sarracenia Purpurea]! Remedy coming soon! #pitcherplant #monkeypox”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Breathe Rite H2O2 Therapy\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Breath Rite H2O2 Therapy at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fbreath-rite-h2o2-therapy-emphysema-copd-fungal-issues:\u003Cbr>\n• “Breath Rite-H2O2 Therapy – Emphysema – COPD [Chronic obstructive pulmonary disease] – Fungal Issues”\u003Cbr>\n• “Emphysema and Cancer treatment. H2O2 is used for. Breaking up infections in the lungs and opens up the small capillaries that allows more oxygen through. If you have cancer, flooding the body with oxygen is crucial for the destruction of cancer cells. . . H2O2 or ozone therapy are two of the best ways to accomplish this.”\u003Cbr>\n• “THIS PRODUCT IS A COMPANION TO OUR NATURAL CANCER PROTOCOL TREATMENT. FOR BEST RESULTS, WE ALSO SUGGEST COMBINING WITH THESE NATURAL CANCER FIGHTING PRODUCTS:”\u003Cbr>\n&nbsp; &nbsp; o “NATURES ANCER: A potent combination of the top Cancer Fighting Herbs ALL IN ONE!”\u003Cbr>\n&nbsp; &nbsp; o “PURE ZEOLITE POWDER: Cleans the Blood and all major organs, even through the Blood brain barrier, removing toxins, parasites, bacteria and viruses. Remedies ALL Cancers.”\u003Cbr>\n&nbsp; &nbsp; o “CHAGA MUSHROOM: A known powerful Cancer Killer.”\u003Cbr>\n• “MORE USES FOR H2O2 THERAPY\u003Cbr>\n1. Chicken pox [Varicella]\u003Cbr>\n2. Parasites\u003Cbr>\n3. Allergies\u003Cbr>\n4. Insect bites infection\u003Cbr>\n5. Headaches\u003Cbr>\n8. Anemia\u003Cbr>\n9. HIV\u003Cbr>\n10. Arrythmia\u003Cbr>\n11. Influenza\u003Cbr>\n12. Bacterial Infections\u003Cbr>\n13. Liver Cirrhosis\u003Cbr>\n14. Bronchitis\u003Cbr>\n15. Lupus\u003Cbr>\n16. Cancers\u003Cbr>\n17. Cardiovascular disease\u003Cbr>\n18. Parkinsonism\u003Cbr>\n19. Diabetes type 11 [sic]\u003Cbr>\n20. Gingivitis\u003Cbr>\n21. Cerebral vascular disease\u003Cbr>\n22. Bronchitis\u003Cbr>\n23. Chronic Pain Prostatitis\u003Cbr>\n…\u003Cbr>\n26. Chancroid”\u003C\u002Fp>\n\n\u003Cp>On your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies\u003Cbr>\n• August 31, 2022, post: “H202 Therapy, Breathrite Mouth Spray HERE: https:\u002F\u002Forganicheirloomplants.com. #copd #copdawareness #emphysema #cancer”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Nature’s Ancer\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Nature’s Ancer at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fcancer-herbal-natures-ancer-cancer-natural-remedy-herbal-cancer-tinture:\u003Cbr>\n• “Cancer Herbal Remedy, Nature's Ancer, Cancer Natural Remedy, Herbal Cancer Tincture”\u003Cbr>\n• “In formulating this Cancer Herbal Tincture Remedy, we have targeted the very herbs that contain the highest Anti-Cancer properties to not only kill these parasites, but to also support, balance and irradicate them out of your body for optimal healing. Those that include an anti-cancer dietary protocol with these supporting herbs have a higher chance of healing from this disease. The goal is to stop feeding the parasites which many times create Cancers.”\u003Cbr>\n• “Our Anti-Cancer formula is created only with the purest Organic Herbs . . . pure Anti-Cancer herbs with the highest potency sets the stage for the highest success in healing.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies\u003Cbr>\n• April 7, 2022, post with a picture of your Nature’s Ancer product: “Time to kill this Cancer! HERE!: organicheirloomplants.com #cancer”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ivermectwin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Ivermectwin at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fivermectwin-immune-support-dietary-herbal-supplement:\u003Cbr>\n• “Our herbal alternative to Ivermectin”\u003Cbr>\n• “The main herb in our formula has been clinically tested and shown to be 38% more effective than it's [sic] chemical counterpart at 99.6% effective against ALL variants and helps in aiding to stop viral replication ON CONTACT with the blood stream on a cellular level.”\u003Cbr>\n• “It is now clinically proven that most diseases and illnesses are parasitical in nature. This formula kills those parasites within the body . . . These parasites are responsible for C-pneumonia (an actual allergic reaction to parasitical die off), high inflammation in the joints and muscle tissue and prolonged chronic fatigue.”\u003C\u002Fp>\n\n\u003Cp>• “Medicinal Properties: Anti-viral, anti-parasitical, anti-bacterial, antifungal, expectorant, anti-histamine”\u003C\u002Fp>\n\n\u003Cp>The product page for Ivermectwin also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Ivermectwin for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n• \"I have to report after 4 doses and after having confirmed covid 19 for 19 days prior to taking your formula, I have my energy back, brain fog drugged feeling has lifted, and my heart rate has come down to normal. I can feel lungs clearing also, thank you for this medicine.\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Zeolite\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Zeolite at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fzeolite-micronized-clinoptilotite-heavy-metal-detox:\u003Cbr>\n• “Known Benefits of Use:”\u003Cbr>\n&nbsp; &nbsp; o “Supports . . . renal failure”\u003Cbr>\n&nbsp; &nbsp; o “Treats nervous system problems”\u003Cbr>\n&nbsp; &nbsp; o “Treats psoriasis and all skin issues”\u003Cbr>\n&nbsp; &nbsp; o “Treats fibromyalgia”\u003Cbr>\n&nbsp; &nbsp; o “Treats arthritis, bursitis and gout”\u003Cbr>\n&nbsp; &nbsp; o “Treats many herpes viruses”\u003Cbr>\n&nbsp; &nbsp; o “Removes Candida”\u003Cbr>\n&nbsp; &nbsp; o “Normalizes blood pressure”\u003Cbr>\n&nbsp; &nbsp; o “Reverses diabetes”\u003Cbr>\n&nbsp; &nbsp; o “Treats EBV [Epstein-Barr virus] . . . Lymes [sic] and other auto-immune diseases”\u003C\u002Fp>\n\n\u003Cp>Furthermore, promotional literature which accompanies your products includes claims about your Zeolite product, including:\u003C\u002Fp>\n\n\u003Cp>Under the heading, BENEFITS OF ZEOLITE:\u003Cbr>\n “Pulls out and removes . . . viruses out of the bodies [sic] tissues, blood and gut on a cellular level”\u003Cbr>\n “[H]as been known to reverse kidney renal failure”\u003Cbr>\n “Removes\u002Ftreats all viruses including HIV”\u003Cbr>\n “Treats Nervous System problems”\u003Cbr>\n “Treats Psoriasis”\u003Cbr>\n “Treats Fibromyalgia”\u003Cbr>\n “Treats Arthritis, Bursitis, Gout by removing all uric acid and inflammation”\u003Cbr>\n “Treats many Herpes Viruses”\u003Cbr>\n “Treats Mold Toxicity”\u003Cbr>\n “Removes Candida and all fungal issues”\u003Cbr>\n “Normalizes blood pressure”\u003Cbr>\n “Reverses diabetes”\u003Cbr>\n “Treats Lymes [sic] disease”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Chaga Mushroom\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Chaga Mushroom Herbal Tincture on https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fchaga-mushroom-herbal-tincture-immune-system-building-fights-inflammation\u003Cbr>\n• “REDUCES INFLAMMATION: Inflammation is a natural response of your immune system that can protect against disease. However, long-term inflammation is linked to conditions like heart disease and rheumatoid arthritis. chaga extract can positively impact immunity by reducing long-term inflammation and fighting harmful bacteria and viruses.”\u003Cbr>\n• “Prevents and Fights Cancer”\u003Cbr>\n• “Studies show that chaga can prevent and slow cancer growth . . . Chaga extract prevented the growth of cancer in human liver cells. Similar results were observed with cancer cells of the lung, breast, prostate and colon.”\u003Cbr>\n• “Chaga contains the antioxidant triterpene. Test-tube studies reveal that very concentrated triterpene extract can help kill cancer cells”\u003Cbr>\n• “Studies link chaga to lower blood sugar levels. Therefore, it may help manage diabetes”\u003Cbr>\n• “Study in rats with high cholesterol, chaga extract reduced ‘bad’ LDL cholesterol, total cholesterol and triglycerides while increasing antioxidant levels in addition to reducing ‘bad’ LDL cholesterol — chaga increases ‘good’ HDL cholesterol”\u003C\u002Fp>\n\n\u003Cp>On your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies:\u003Cbr>\n• In an April 8, 2022, post: “Chaga Mushroom kills Cancer Cells HERE!: organicheirloomplants.com #cancer”\u003C\u002Fp>\n\n\u003Cp>Your Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act, 21 U.S.C. 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Sara Dent Acosta, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Renewal of Determination that a Public Health Emergency Exists (issued Nov. 2, 2022), available at \u003Ca href=\"https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fmpx-renewal-2Nov2022.aspx\">https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fmpx-renewal-2Nov2022.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> HHS has adopted the World Health Organization’s renaming of monkey pox to “mpox” to reduce stigma. Department of Health and Human Services, Biden Harris Administration Supports the World Health Organization Renaming of Monkeypox to mpox (issued Nov. 28, 2022), available at \u003Ca href=\"https:\u002F\u002Fwww.hhs.gov\u002Fabout\u002Fnews\u002F2022\u002F11\u002F28\u002Fbiden-harris-administration-supports-the-world-health-organization-renaming-of-monkeypox-to-mpox.html\">https:\u002F\u002Fwww.hhs.gov\u002Fabout\u002Fnews\u002F2022\u002F11\u002F28\u002Fbiden-harris-administration-supports-the-world-health-organization-renaming-of-monkeypox-to-mpox.html\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nWendy Wiegert\n\nOrganic Heirloom Plants\n\n51594 Boston Road\n\nHancock, MI 49930\n\nUnited States\n\ninfo@organicheirloomplants.com\n\norganicheirloomplants@yahoo.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nRE: CMS # 643997\n\nDear Ms. Wiegert:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Forganicheirloomplants.com in October 2022. We also reviewed your promotional literature that accompanies your products and your social media website at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies, where you direct consumers to your website, https:\u002F\u002Forganicheirloomplants.com, to purchase your products Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Ivermectwin, Nature’s Ancer, Zeolite, and Chaga Mushroom. Based on our review, the claims on your websites and promotional literature establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Act, 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the Act, 21 U.S.C. § 352. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nThe Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving mpox.1,2 Therefore, FDA is taking measures to protect customers from products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure mpox. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure mpox in people. We request that you cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of mpox.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as a drug include the following:\n\nSarracenia Purpurea\n\nOn the product webpage for Sarracenia Purpurea at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fmonkey-pox-sarracenia-purpurea-herbal-natural-remedy-herbal-tincture:\n\n• “Monkey Pox, Sarracenia Purpurea, Herbal Natural Remedy”\n\n• “For decades, research has shown the effectiveness of Sarracenia Purpurea (Pitcher Plant) against past outbreaks of small pox [sic] in the 19th Century, found to halt viral replication in viral, derived from the Variola Virus also associated with Monkey Pox.”\n\nThe above noted claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Forganicheirloomplants.com through Internet searches. The metatags include:\n\n• “Monkey Pox, Sarracenia Purpurea, Herbal Natural Remedy”\n\nOn your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies:\n\n• In a May 30, 2022, post: “Harvesting Pitcher Plant [another name for Sarracenia Purpurea]! Remedy coming soon! #pitcherplant #monkeypox”\n\nBreathe Rite H2O2 Therapy\n\nOn the product webpage for Breath Rite H2O2 Therapy at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fbreath-rite-h2o2-therapy-emphysema-copd-fungal-issues:\n\n• “Breath Rite-H2O2 Therapy – Emphysema – COPD [Chronic obstructive pulmonary disease] – Fungal Issues”\n\n• “Emphysema and Cancer treatment. H2O2 is used for. Breaking up infections in the lungs and opens up the small capillaries that allows more oxygen through. If you have cancer, flooding the body with oxygen is crucial for the destruction of cancer cells. . . H2O2 or ozone therapy are two of the best ways to accomplish this.”\n\n• “THIS PRODUCT IS A COMPANION TO OUR NATURAL CANCER PROTOCOL TREATMENT. FOR BEST RESULTS, WE ALSO SUGGEST COMBINING WITH THESE NATURAL CANCER FIGHTING PRODUCTS:”\n\no “NATURES ANCER: A potent combination of the top Cancer Fighting Herbs ALL IN ONE!”\n\no “PURE ZEOLITE POWDER: Cleans the Blood and all major organs, even through the Blood brain barrier, removing toxins, parasites, bacteria and viruses. Remedies ALL Cancers.”\n\no “CHAGA MUSHROOM: A known powerful Cancer Killer.”\n\n• “MORE USES FOR H2O2 THERAPY\n\n1. Chicken pox [Varicella]\n\n2. Parasites\n\n3. Allergies\n\n4. Insect bites infection\n\n5. Headaches\n\n8. Anemia\n\n9. HIV\n\n10. Arrythmia\n\n11. Influenza\n\n12. Bacterial Infections\n\n13. Liver Cirrhosis\n\n14. Bronchitis\n\n15. Lupus\n\n16. Cancers\n\n17. Cardiovascular disease\n\n18. Parkinsonism\n\n19. Diabetes type 11 [sic]\n\n20. Gingivitis\n\n21. Cerebral vascular disease\n\n22. Bronchitis\n\n23. Chronic Pain Prostatitis\n\n…\n\n26. Chancroid”\n\nOn your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies\n\n• August 31, 2022, post: “H202 Therapy, Breathrite Mouth Spray HERE: https:\u002F\u002Forganicheirloomplants.com. #copd #copdawareness #emphysema #cancer”\n\nNature’s Ancer\n\nOn the product webpage for Nature’s Ancer at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fcancer-herbal-natures-ancer-cancer-natural-remedy-herbal-cancer-tinture:\n\n• “Cancer Herbal Remedy, Nature's Ancer, Cancer Natural Remedy, Herbal Cancer Tincture”\n\n• “In formulating this Cancer Herbal Tincture Remedy, we have targeted the very herbs that contain the highest Anti-Cancer properties to not only kill these parasites, but to also support, balance and irradicate them out of your body for optimal healing. Those that include an anti-cancer dietary protocol with these supporting herbs have a higher chance of healing from this disease. The goal is to stop feeding the parasites which many times create Cancers.”\n\n• “Our Anti-Cancer formula is created only with the purest Organic Herbs . . . pure Anti-Cancer herbs with the highest potency sets the stage for the highest success in healing.”\n\nOn your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies\n\n• April 7, 2022, post with a picture of your Nature’s Ancer product: “Time to kill this Cancer! HERE!: organicheirloomplants.com #cancer”\n\nIvermectwin\n\nOn the product webpage for Ivermectwin at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fivermectwin-immune-support-dietary-herbal-supplement:\n\n• “Our herbal alternative to Ivermectin”\n\n• “The main herb in our formula has been clinically tested and shown to be 38% more effective than it's [sic] chemical counterpart at 99.6% effective against ALL variants and helps in aiding to stop viral replication ON CONTACT with the blood stream on a cellular level.”\n\n• “It is now clinically proven that most diseases and illnesses are parasitical in nature. This formula kills those parasites within the body . . . These parasites are responsible for C-pneumonia (an actual allergic reaction to parasitical die off), high inflammation in the joints and muscle tissue and prolonged chronic fatigue.”\n\n• “Medicinal Properties: Anti-viral, anti-parasitical, anti-bacterial, antifungal, expectorant, anti-histamine”\n\nThe product page for Ivermectwin also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Ivermectwin for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\n• \"I have to report after 4 doses and after having confirmed covid 19 for 19 days prior to taking your formula, I have my energy back, brain fog drugged feeling has lifted, and my heart rate has come down to normal. I can feel lungs clearing also, thank you for this medicine.\"\n\nZeolite\n\nOn the product webpage for Zeolite at https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fzeolite-micronized-clinoptilotite-heavy-metal-detox:\n\n• “Known Benefits of Use:”\n\no “Supports . . . renal failure”\n\no “Treats nervous system problems”\n\no “Treats psoriasis and all skin issues”\n\no “Treats fibromyalgia”\n\no “Treats arthritis, bursitis and gout”\n\no “Treats many herpes viruses”\n\no “Removes Candida”\n\no “Normalizes blood pressure”\n\no “Reverses diabetes”\n\no “Treats EBV [Epstein-Barr virus] . . . Lymes [sic] and other auto-immune diseases”\n\nFurthermore, promotional literature which accompanies your products includes claims about your Zeolite product, including:\n\nUnder the heading, BENEFITS OF ZEOLITE:\n\n “Pulls out and removes . . . viruses out of the bodies [sic] tissues, blood and gut on a cellular level”\n\n “[H]as been known to reverse kidney renal failure”\n\n “Removes\u002Ftreats all viruses including HIV”\n\n “Treats Nervous System problems”\n\n “Treats Psoriasis”\n\n “Treats Fibromyalgia”\n\n “Treats Arthritis, Bursitis, Gout by removing all uric acid and inflammation”\n\n “Treats many Herpes Viruses”\n\n “Treats Mold Toxicity”\n\n “Removes Candida and all fungal issues”\n\n “Normalizes blood pressure”\n\n “Reverses diabetes”\n\n “Treats Lymes [sic] disease”\n\nChaga Mushroom\n\nOn the product webpage for Chaga Mushroom Herbal Tincture on https:\u002F\u002Forganicheirloomplants.com\u002Fshop\u002Fols\u002Fproducts\u002Fchaga-mushroom-herbal-tincture-immune-system-building-fights-inflammation\n\n• “REDUCES INFLAMMATION: Inflammation is a natural response of your immune system that can protect against disease. However, long-term inflammation is linked to conditions like heart disease and rheumatoid arthritis. chaga extract can positively impact immunity by reducing long-term inflammation and fighting harmful bacteria and viruses.”\n\n• “Prevents and Fights Cancer”\n\n• “Studies show that chaga can prevent and slow cancer growth . . . Chaga extract prevented the growth of cancer in human liver cells. Similar results were observed with cancer cells of the lung, breast, prostate and colon.”\n\n• “Chaga contains the antioxidant triterpene. Test-tube studies reveal that very concentrated triterpene extract can help kill cancer cells”\n\n• “Studies link chaga to lower blood sugar levels. Therefore, it may help manage diabetes”\n\n• “Study in rats with high cholesterol, chaga extract reduced ‘bad’ LDL cholesterol, total cholesterol and triglycerides while increasing antioxidant levels in addition to reducing ‘bad’ LDL cholesterol — chaga increases ‘good’ HDL cholesterol”\n\nOn your Facebook Social Media page at https:\u002F\u002Ffacebook.com\u002Fgodgivenherbalremedies:\n\n• In an April 8, 2022, post: “Chaga Mushroom kills Cancer Cells HERE!: organicheirloomplants.com #cancer”\n\nYour Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act, 21 U.S.C. 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your Sarracenia Purpurea, Breathe Rite H2O2 Therapy, Nature’s Ancer, Ivermectwin, Zeolite, and Chaga Mushroom products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Sara Dent Acosta, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\n____________________________\n\n1 Secretary of Health and Human Services, Renewal of Determination that a Public Health Emergency Exists (issued Nov. 2, 2022), available at https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fmpx-renewal-2Nov2022.aspx.\n\n2 HHS has adopted the World Health Organization’s renaming of monkey pox to “mpox” to reduce stigma. Department of Health and Human Services, Biden Harris Administration Supports the World Health Organization Renaming of Monkeypox to mpox (issued Nov. 28, 2022), available at https:\u002F\u002Fwww.hhs.gov\u002Fabout\u002Fnews\u002F2022\u002F11\u002F28\u002Fbiden-harris-administration-supports-the-world-health-organization-renaming-of-monkeypox-to-mpox.html.","Organic Heirloom Plants","organic-heirloom-plants-643997-01302023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganic-heirloom-plants-643997-01302023","2026-10-26T08:09:39.096614+00:00","2023-01-31","643997","Wendy Wiegert","2026-08-20T01:17:23.513+00:00","2023-01-30",{"id":163,"raw":164,"subject":168,"body_html":169,"body_text":170,"firm_name":171,"letter_id":172,"created_at":173,"fei_number":20,"letter_url":174,"updated_at":175,"action_type":23,"case_status":24,"posted_date":176,"marcs_cms_no":177,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":178,"body_fetched_at":179,"delivery_method":180,"recipient_title":20,"reference_number":20,"action_taken_date":181,"medical_device_id":20,"response_letter_date":20},21688,[165,166,167,38,168,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganicare-llc-organicare-natures-science-llc-734925-10012026\">OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Caroline Goodner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3900 Drossett Dr., Bldg 5, Suite G\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78744\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@femiclear.com\"> hello@femiclear.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 734925\u003C\u002Fp>\u003Cp>To Caroline Goodner:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Ffemiclear.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “HClear for him” and “FemiClear Genital Herpes Symptoms” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Ffemiclear.com\u002F in July 2026. We have also reviewed your Facebook and Instagram accounts at https:\u002F\u002Fwww.facebook.com\u002FFemiClear and \u003Ca href=\"https:\u002F\u002Fwww.instagram.com\u002Ffemiclear,\">https:\u002F\u002Fwww.instagram.com\u002Ffemiclear,\u003C\u002Fa> respectively, where you direct consumers to your https:\u002F\u002Ffemiclear.com\u002F website to purchase your products. Based on our review, “HClear for him” and “FemiClear Genital Herpes Symptoms” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “HClear for him” and “FemiClear Genital Herpes Symptoms” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and social media accounts, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>HClear for him\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Fhclear-for-him-for-genital-herpes-symptoms-24-ea?selling_plan=3741548730:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “&gt;90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\u003Cbr>o “GENITAL HERPES SYMPTOMS”\u003Cbr>o “FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN &amp; BURNING”\u003C\u002Fli>\u003Cli>“Try the FemiClear topical ointment for men that kills 99.9% of the herpes simplex I &amp; II viruses”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On a September 10, 2024, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002FFemiClear\u002Fposts\u002Fpfbid02GZLSvy4rJUch7SvLwKcZbP8r5aAipKeCruw7qjkDnjKVLigQPhSu8i7CroLJf6cjl:\u003C\u002Fp>\u003Cul>\u003Cli>“Say goodbye to the discomfort of genital herpes symptoms with HClear for Him! This all-natural, organic ointment is designed specifically for men, targeting itching, tingling, and burning caused by herpes outbreaks. With a powerful formula that kills 99.9% of herpes simplex viruses (HSV1 &amp; HSV2), you can trust HClear to bring fast relief. Over 90% of users reported milder symptoms, and over 50% experienced no blisters when used at the first sign.”\u003C\u002Fli>\u003Cli>“Explore The Benefits HClear for Him for Genital Herpes Symptoms”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>FemiClear Genital Herpes Symptoms\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multi3symptom?selling_plan=3740434618:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “Fast-acting ointment for recurring outbreak symptoms”\u003Cbr>o “&gt;90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\u003C\u002Fli>\u003Cli>“Looking for genital herpes symptom relief? Try the FemiClear topical ointment that kills 99.9% of the herpes simplex I &amp; II viruses (HSV1 &amp; HSV2) and works fast to relieve Itching &amp; Tingling + Pain &amp; Burning symptoms caused by a herpes outbreak.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On a January 29, 2026, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002Fphoto.php?fbid=1343141094494950&amp;set=pb.100063972160769.-2207520000&amp;type=3:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “GENITAL HERPES SYMPTOMS\u003Cbr>Fast-acting ointment for recurring outbreak symptoms”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On an April 4, 2025, post on your Instagram page https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDICmMYfOANa\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Herpes Relief for Less”\u003C\u002Fli>\u003Cli>“Genital Herpes Symptoms”\u003C\u002Fli>\u003Cli>“We know managing outbreak symptoms can be tough. The last thing you need is a price tag standing between you and relief. That’s why we dropped the price of FemiClear for Genital Herpes Symptoms.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and\u002For to affect the structure or function of the body. Examples of such testimonials include, but are not limited to, the following from the Reviews section of the “FemiClear Genital Herpes Symptoms” product webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multisymptom?selling_plan=3740434618:\u003C\u002Fp>\u003Cul>\u003Cli>“Works like magic!\u003Cbr>I have had genital herpes for 35 years, and in the past 15 years, the outbreaks have been horrible and hard to get rid of. I won't take meds because they mess up my stomach. However, this ointment effectively eliminates the blisters within 24 hours. I have tried EVERYTHING, and this product truly works.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“HClear for him” and “FemiClear Genital Herpes Symptoms” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “734925” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “HClear for him” and “FemiClear Genital Herpes Symptoms” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your products include lemongrass, which is not listed in the HPUS; thus, these products fall outside the scope of products addressed in this guidance.\u003C\u002Fp>\u003Cp>Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nCaroline Goodner\n\nRecipient Title\n\nChief Executive Officer\n\nOrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\n\n3900 Drossett Dr., Bldg 5, Suite G\n\nAustin, TX 78744\n\nUnited States\n\nhello@femiclear.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 734925\nTo Caroline Goodner:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Ffemiclear.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “HClear for him” and “FemiClear Genital Herpes Symptoms” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Ffemiclear.com\u002F in July 2026. We have also reviewed your Facebook and Instagram accounts at https:\u002F\u002Fwww.facebook.com\u002FFemiClear and https:\u002F\u002Fwww.instagram.com\u002Ffemiclear, respectively, where you direct consumers to your https:\u002F\u002Ffemiclear.com\u002F website to purchase your products. Based on our review, “HClear for him” and “FemiClear Genital Herpes Symptoms” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “HClear for him” and “FemiClear Genital Herpes Symptoms” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and social media accounts, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nHClear for him\nOn the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Fhclear-for-him-for-genital-herpes-symptoms-24-ea?selling_plan=3741548730:\nOn the image of the product\no “>90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\no “GENITAL HERPES SYMPTOMS”\no “FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN & BURNING”\n“Try the FemiClear topical ointment for men that kills 99.9% of the herpes simplex I & II viruses”\nOn a September 10, 2024, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002FFemiClear\u002Fposts\u002Fpfbid02GZLSvy4rJUch7SvLwKcZbP8r5aAipKeCruw7qjkDnjKVLigQPhSu8i7CroLJf6cjl:\n“Say goodbye to the discomfort of genital herpes symptoms with HClear for Him! This all-natural, organic ointment is designed specifically for men, targeting itching, tingling, and burning caused by herpes outbreaks. With a powerful formula that kills 99.9% of herpes simplex viruses (HSV1 & HSV2), you can trust HClear to bring fast relief. Over 90% of users reported milder symptoms, and over 50% experienced no blisters when used at the first sign.”\n“Explore The Benefits HClear for Him for Genital Herpes Symptoms”\nFemiClear Genital Herpes Symptoms\nOn the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multi3symptom?selling_plan=3740434618:\nOn the image of the product\no “Fast-acting ointment for recurring outbreak symptoms”\no “>90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\n“Looking for genital herpes symptom relief? Try the FemiClear topical ointment that kills 99.9% of the herpes simplex I & II viruses (HSV1 & HSV2) and works fast to relieve Itching & Tingling + Pain & Burning symptoms caused by a herpes outbreak.”\nOn a January 29, 2026, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002Fphoto.php?fbid=1343141094494950&set=pb.100063972160769.-2207520000&type=3:\nOn the image of the product\no “GENITAL HERPES SYMPTOMS\nFast-acting ointment for recurring outbreak symptoms”\nOn an April 4, 2025, post on your Instagram page https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDICmMYfOANa\u002F:\n“Herpes Relief for Less”\n“Genital Herpes Symptoms”\n“We know managing outbreak symptoms can be tough. The last thing you need is a price tag standing between you and relief. That’s why we dropped the price of FemiClear for Genital Herpes Symptoms.”\nAdditionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and\u002For to affect the structure or function of the body. Examples of such testimonials include, but are not limited to, the following from the Reviews section of the “FemiClear Genital Herpes Symptoms” product webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multisymptom?selling_plan=3740434618:\n“Works like magic!\nI have had genital herpes for 35 years, and in the past 15 years, the outbreaks have been horrible and hard to get rid of. I won't take meds because they mess up my stomach. However, this ointment effectively eliminates the blisters within 24 hours. I have tried EVERYTHING, and this product truly works.”\n“HClear for him” and “FemiClear Genital Herpes Symptoms” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.1 Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “734925” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n___________________\n1 We recognize that the “HClear for him” and “FemiClear Genital Herpes Symptoms” labeling describes the products as being “homeopathic.”\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your products include lemongrass, which is not listed in the HPUS; thus, these products fall outside the scope of products addressed in this guidance.\nNotwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC","organicare-llc-organicare-natures-science-llc-734925-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganicare-llc-organicare-natures-science-llc-734925-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","734925","Caroline Goodner","2026-10-14T12:33:25.038+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":183,"raw":184,"subject":40,"body_html":188,"body_text":189,"firm_name":190,"letter_id":191,"created_at":45,"fei_number":20,"letter_url":192,"updated_at":193,"action_type":23,"case_status":24,"posted_date":194,"marcs_cms_no":195,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":196,"body_fetched_at":197,"delivery_method":98,"recipient_title":20,"reference_number":198,"action_taken_date":199,"medical_device_id":20,"response_letter_date":20},715,[185,186,187,38,40,13,13,13],"\u003Ctime datetime=\"2025-08-19T04:00:00Z\">08\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-11T04:00:00Z\">08\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverlaan-organics-inc-dba-maple-organics-707956-08112025\">Everlaan Organics, Inc. dba Maple Organics\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-99\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rosy Atwal\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everlaan Organics, Inc. dba Maple Organics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17220 Heather Dr, Unit 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Surrey\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V3S 8G6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-99\u003C\u002Fp>\u003Cp>August 11, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Atwal:\u003C\u002Fp>\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 4, 2024 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Everlaan Organics, Inc., dba Maple Organics, FEI 3025798567, 17220 Heather Dr, Unit 106, Surrey, British Columbia, Canada.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>In addition, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Furthermore, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are misbranded under 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Additionally, “maple organics Cough &amp; Cold Relief” is further misbranded under 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1) and “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough &amp; Cold Relief” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture OTC drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States.\u003C\u002Fp>\u003Cp>In your initial response, you state that you test each batch of your finished drug products before release. However, when FDA requested you to provide the test data, you failed to provide any records demonstrating that you tested your finished products prior to release. You do not appear to be performing release testing on finished products.\u003C\u002Fp>\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including adequate test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided about the manufacture of your OTC drug products, you did not demonstrate that you are adequately testing each shipment of each lot of incoming components.\u003C\u002Fp>\u003Cp>In response to our initial request, you state that you “identify all items via receiving practices” and provided a receiving procedure. However, the procedure did not specify chemical identity testing for incoming components. You also did not provide your incoming component testing data for the most recent batches shipped to the United States when asked by FDA subsequently.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided did not demonstrate that you have an adequate stability program for the OTC drug products you manufacture. You provided a stability test procedure that only discussed accelerated stability testing but did not include long-term stability testing. In lieu of stability data, you provided a cost estimate from a contract testing laboratory outlining the various stability tests to be performed. We note that one of your microbiological test references USP &lt;2021&gt;, which is intended for evaluating nutritional supplements, and not drug products.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The batch records you provided in response to our request for records lacked adequate production details regarding significant manufacturing steps, including, but not limited to, identity of major equipment and lines, in-process controls, yield, and container closures. This documentation is necessary to establish that manufacturing processes were consistently followed and are reproducible. Having incomplete records deprives you of traceability of actions necessary for investigational purposes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components, approval or rejection of finished drug products, batch record review, establishment and implementation of an adequate stability study program, and performance of adequate process validation.\u003C\u002Fp>\u003Cp>Your procedures did not define your QU structure and delineation of QU roles and responsibilities. We acknowledge that you plan to cease production and seek a contract manufacturing organization (CMO), \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that your prospective contract manufacturing facility, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was placed on Import Alert 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for failure to comply with CGMP requirements. Drugs manufactured at your prospective CMO are considered adulterated and thus should not be used for the manufacture of drugs for the United States market. It is your responsibility to perform adequate due diligence to ensure that your CMO is in full compliance with CGMPs, the applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims observed on the product labels and labeling from your website listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Joint Pain Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves joint pain.” [from the product label]\u003Cbr>• “Maple Organics Joint Therapy is an FDA-approved, all-natural formula designed to relieve pain, stiffness, and inflammation.” [from the product website www.mapleorganics.com]\u003Cbr>• “Made with organic Arnica Montana, known for its anti-inflammatory and analgesic properties, this balm provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>• “Unlike conventional ointments, our steroid-free formula helps reduce muscle damage, so you can feel better without the harsh side effects.” [from the product website www.mapleorganics.com]\u003Cbr>• “A remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Muscle Pain Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves minor aches and pains of muscles and joints associated with simple backache, strains and bruises.” [from the product label]\u003Cbr>• “This is not an icy hot product but will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Cough &amp; Cold Relief for Kids\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves cough associated with the common cold.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>“maple organics Cough &amp; Cold Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS…Uses:\u003C\u002Fstrong> Temporarily relieves cough associated with the common cold.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to external analgesic drug products, such as your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here the External Analgesic Drug Products for Over-the-Counter Human Use (M017).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” do not conform to the conditions specified in M017 for the reasons described below\u003C\u002Fp>\u003Cp>Specifically, “maple organics Joint Pain Relief” contains the active ingredient arnica, which is not a permitted active ingredient under M017. 21 CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although your firm does not specifically list arnica as an active ingredient, your labeling of “maple organics Joint Pain Relief,” such as your website, includes statements that claim arnica is intended as an anti-inflammatory and analgesic, and “…provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” Such statements demonstrate that arnica is an “active ingredient” in your “maple organics Joint Pain Relief” because it is intended to furnish pharmacological activity or other direct effect to affect the structure or any function of the body of humans. Because arnica is not an active ingredient permitted under M017, your “maple organics Joint Pain Relief” does not conform with the conditions set forth in M017.\u003C\u002Fp>\u003Cp>Furthermore, the labeling for “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” include intended uses that are not permitted in M017. For example, you claim that “maple organic Joint Pain Relief” will “help reduce muscle damage” and it can be used as “a remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” In addition, you claim that “maple organic Muscle Pain Relief” “…will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” Such intended uses do not conform with M017.50(b).\u003C\u002Fp>\u003Cp>Thus, as formulated and labeled, your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” products do not comply with the applicable final administrative order described above or any other final order.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “maple organics Joint Pain Relief” product is misbranded under section 502(a) because the website labeling claims the product is “…an FDA-approved, all-natural formula….” This claim suggests that the drug is approved or legally marketable (see 21 CFR 207.77(b)). However, your product is not subject to an FDA-approved application. Therefore, your labeling representation suggesting that your product is FDA-approved is false or misleading.\u003C\u002Fp>\u003Cp>Further, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are misbranded under 502(a) because your products’ labels claim ”At Maple Organics, we scientifically validate natural remedies to FDA standards, ensuring their efficacy….” This claim misleadingly suggests that your products are validated to FDA-standards when such is not the case.\u003C\u002Fp>\u003Cp>We note that, based on the labeling evidence described above, “maple organics Cough &amp; Cold Relief” is intended for use as topical antitussives under M012 (Cold, Cough Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use). Your “maple organics Cough &amp; Cold Relief” product is misbranded under section 502(f)(1) because the product label is missing adequate directions for use specified in M012.74(d)(2)(i) and M012.74(d)(2)(ii). Specifically, the directions on the product label are missing the following statement, “Children under 2 years of age: Ask a doctor.”\u003C\u002Fp>\u003Cp>Additionally, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough &amp; Cold Relief” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on May 23, 2025. Additionally, FDA placed your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” drug products on Import Alert 66-41 on June 30, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Everlaan Organics, Inc., dba Maple Organics, 17220 Heather Dr, Unit 106 Surrey, British Columbia, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3025798567 and ATTN: William Yang.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&amp;C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch\u002Forder_otc000033.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-99\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Rosy Atwal\n\nRecipient Title\n\nFounder and CEO\n\nEverlaan Organics, Inc. dba Maple Organics\n\n17220 Heather Dr, Unit 106\n\nSurrey BC V3S 8G6\n\nCanada\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-99\nAugust 11, 2025\nDear Ms. Atwal:\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 4, 2024 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Everlaan Organics, Inc., dba Maple Organics, FEI 3025798567, 17220 Heather Dr, Unit 106, Surrey, British Columbia, Canada.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\nIn addition, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Furthermore, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are misbranded under 502(a) of the FD&C Act, 21 U.S.C. 352(a). Additionally, “maple organics Cough & Cold Relief” is further misbranded under 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1) and “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough & Cold Relief” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYou manufacture OTC drug products, including (b)(4) products for (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States.\nIn your initial response, you state that you test each batch of your finished drug products before release. However, when FDA requested you to provide the test data, you failed to provide any records demonstrating that you tested your finished products prior to release. You do not appear to be performing release testing on finished products.\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including adequate test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\nBased on the records and information you provided about the manufacture of your OTC drug products, you did not demonstrate that you are adequately testing each shipment of each lot of incoming components.\nIn response to our initial request, you state that you “identify all items via receiving practices” and provided a receiving procedure. However, the procedure did not specify chemical identity testing for incoming components. You also did not provide your incoming component testing data for the most recent batches shipped to the United States when asked by FDA subsequently.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\nA summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nThe records and information you provided did not demonstrate that you have an adequate stability program for the OTC drug products you manufacture. You provided a stability test procedure that only discussed accelerated stability testing but did not include long-term stability testing. In lieu of stability data, you provided a cost estimate from a contract testing laboratory outlining the various stability tests to be performed. We note that one of your microbiological test references USP \u003C2021>, which is intended for evaluating nutritional supplements, and not drug products.\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\nThe batch records you provided in response to our request for records lacked adequate production details regarding significant manufacturing steps, including, but not limited to, identity of major equipment and lines, in-process controls, yield, and container closures. This documentation is necessary to establish that manufacturing processes were consistently followed and are reproducible. Having incomplete records deprives you of traceability of actions necessary for investigational purposes.\nIn response to this letter, provide:\n• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\n• A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n5. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components, approval or rejection of finished drug products, batch record review, establishment and implementation of an adequate stability study program, and performance of adequate process validation.\nYour procedures did not define your QU structure and delineation of QU roles and responsibilities. We acknowledge that you plan to cease production and seek a contract manufacturing organization (CMO), (b)(4), to manufacture your drug products.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nUse of Contract Manufacturers\nWe note that your prospective contract manufacturing facility, (b)(4), was placed on Import Alert 66-40 on (b)(4) for failure to comply with CGMP requirements. Drugs manufactured at your prospective CMO are considered adulterated and thus should not be used for the manufacture of drugs for the United States market. It is your responsibility to perform adequate due diligence to ensure that your CMO is in full compliance with CGMPs, the applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nUnapproved New Drug and Misbranding Violations\n“maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\nExamples of claims observed on the product labels and labeling from your website listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n“maple organics Joint Pain Relief”\n• “DRUG FACTS . . . Uses: Temporarily relieves joint pain.” [from the product label]\n• “Maple Organics Joint Therapy is an FDA-approved, all-natural formula designed to relieve pain, stiffness, and inflammation.” [from the product website www.mapleorganics.com]\n• “Made with organic Arnica Montana, known for its anti-inflammatory and analgesic properties, this balm provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\n• “Unlike conventional ointments, our steroid-free formula helps reduce muscle damage, so you can feel better without the harsh side effects.” [from the product website www.mapleorganics.com]\n• “A remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\n“maple organics Muscle Pain Relief”\n• “DRUG FACTS . . . Uses: Temporarily relieves minor aches and pains of muscles and joints associated with simple backache, strains and bruises.” [from the product label]\n• “This is not an icy hot product but will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” [from the product website www.mapleorganics.com]\n“maple organics Cough & Cold Relief for Kids”\n• “DRUG FACTS . . . Uses: Temporarily relieves cough associated with the common cold.” [from the product label]\n“maple organics Cough & Cold Relief”\n• “DRUG FACTS…Uses: Temporarily relieves cough associated with the common cold.” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to external analgesic drug products, such as your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here the External Analgesic Drug Products for Over-the-Counter Human Use (M017).2 However, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” do not conform to the conditions specified in M017 for the reasons described below\nSpecifically, “maple organics Joint Pain Relief” contains the active ingredient arnica, which is not a permitted active ingredient under M017. 21 CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although your firm does not specifically list arnica as an active ingredient, your labeling of “maple organics Joint Pain Relief,” such as your website, includes statements that claim arnica is intended as an anti-inflammatory and analgesic, and “…provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” Such statements demonstrate that arnica is an “active ingredient” in your “maple organics Joint Pain Relief” because it is intended to furnish pharmacological activity or other direct effect to affect the structure or any function of the body of humans. Because arnica is not an active ingredient permitted under M017, your “maple organics Joint Pain Relief” does not conform with the conditions set forth in M017.\nFurthermore, the labeling for “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” include intended uses that are not permitted in M017. For example, you claim that “maple organic Joint Pain Relief” will “help reduce muscle damage” and it can be used as “a remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” In addition, you claim that “maple organic Muscle Pain Relief” “…will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” Such intended uses do not conform with M017.50(b).\nThus, as formulated and labeled, your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” products do not comply with the applicable final administrative order described above or any other final order.3 Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nYour “maple organics Joint Pain Relief” product is misbranded under section 502(a) because the website labeling claims the product is “…an FDA-approved, all-natural formula….” This claim suggests that the drug is approved or legally marketable (see 21 CFR 207.77(b)). However, your product is not subject to an FDA-approved application. Therefore, your labeling representation suggesting that your product is FDA-approved is false or misleading.\nFurther, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are misbranded under 502(a) because your products’ labels claim ”At Maple Organics, we scientifically validate natural remedies to FDA standards, ensuring their efficacy….” This claim misleadingly suggests that your products are validated to FDA-standards when such is not the case.\nWe note that, based on the labeling evidence described above, “maple organics Cough & Cold Relief” is intended for use as topical antitussives under M012 (Cold, Cough Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use). Your “maple organics Cough & Cold Relief” product is misbranded under section 502(f)(1) because the product label is missing adequate directions for use specified in M012.74(d)(2)(i) and M012.74(d)(2)(ii). Specifically, the directions on the product label are missing the following statement, “Children under 2 years of age: Ask a doctor.”\nAdditionally, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough & Cold Relief” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on May 23, 2025. Additionally, FDA placed your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” drug products on Import Alert 66-41 on June 30, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Everlaan Organics, Inc., dba Maple Organics, 17220 Heather Dr, Unit 106 Surrey, British Columbia, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3025798567 and ATTN: William Yang.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch\u002Forder_otc000033.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Everlaan Organics, Inc. dba Maple Organics","everlaan-organics-inc-dba-maple-organics-707956-08112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverlaan-organics-inc-dba-maple-organics-707956-08112025","2026-10-26T08:08:37.155625+00:00","2025-08-19","707956","Ms. Rosy Atwal","2026-08-19T16:29:48.848+00:00","320-25-99","2025-08-11",{"id":201,"raw":202,"subject":168,"body_html":207,"body_text":208,"firm_name":209,"letter_id":210,"created_at":112,"fei_number":20,"letter_url":211,"updated_at":212,"action_type":23,"case_status":24,"posted_date":213,"marcs_cms_no":214,"product_type":70,"closeout_date":20,"issuing_office":38,"recipient_name":20,"body_fetched_at":215,"delivery_method":216,"recipient_title":20,"reference_number":20,"action_taken_date":217,"medical_device_id":20,"response_letter_date":20},456,[203,204,205,38,206,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-17T05:00:00Z\">11\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvarunkart-group-llc-dba-organic-wellnesses-716154-11172025\">VarunKart Group LLC dba Organic Wellnesses\u003C\u002Fa>","Unapproved New Drugs\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>VarunKart Group LLC dba Organic Wellnesses\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8206 Louisiana Blvd NE, STE A #4959\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87113\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@organicwellnesses.com\"> support@organicwellnesses.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 716154\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>VarunKart Group LLC:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Forganicwellnesses.com\u002F in September 2025. The FDA has observed that your website offers “Lord's L 143 Measles Drop,” “Dabur Swarna Bhasma,” “Dr. Willmar Schwabe India Aviaire Dilution,” “Himalaya Pure Herbs Arjuna Cardiac Wellness,” “Muniyal Muniojus Tablets,” “Mohammedia Kalonji Oil,” “Patanjali Divya Godhan Ark (Gaumutra),” “Himalaya Ophthacare Eye Drops” and “Patanjali Drishti Eye Drop” (hereinafter Organic Wellnesses products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Your Organic Wellnesses products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Lord's L 143 Measles Drop,” “Dabur Swarna Bhasma,” “Dr. Willmar Schwabe India Aviaire Dilution,” “Himalaya Pure Herbs Arjuna Cardiac Wellness,” “Muniyal Muniojus Tablets,” “Mohammedia Kalonji Oil,” and “Patanjali Divya Godhan Ark (Gaumutra)” drug products includes claims to cure, mitigate, treat, or prevent serious and\u002For life-threatening conditions such as measles, syphilis, tuberculosis, cancer, diabetes, and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process. In addition, your unapproved “Himalaya Ophthacare Eye Drops” and “Patanjali Drishti Eye Drop” drug products are concerning because ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\u003Cp>Based on a review of your website, your Organic Wellnesses products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Lord's L 143 Measles Drop\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Flords-l-143-measles-drop-30-ml:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Measles Drops”\u003C\u002Fli>\u003Cli>“It is beneficial for measles and fever\u003Cbr>It helps to reduce mild to high temperatures\u003Cbr>It is beneficial for cough, blisters, watery nose, and eyes”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Dabur Swarna Bhasma\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fdabur-swarna-bhasma-500-mgs:\u003C\u002Fp>\u003Cul>\u003Cli>“This ayurvedic medicine improves muscle strength and helps in all diseases like muscular dystrophy.”\u003C\u002Fli>\u003Cli>“Specially prescribed in hemiplegia and complete paralysis.”\u003C\u002Fli>\u003Cli>“Effectively treat Malabsorption syndrome, dyspepsia, hiccup, anaemia, dyspnoea, asthma, fever, tissue wasting, tuberculosis, impaired intelligence, epilepsy, rupture \u002F weakness of ligaments, heart disease, disease due to Vata dosha, syphilis, poison, loss of memory, mania, psychosis, hoarseness of voice, diseases of skin, senility\u002Fprogeriasis”\u003C\u002Fli>\u003Cli>“Exceptional efficacy in skin ailments and syphilis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Dr. Willmar Schwabe India Aviaire Dilution\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fdr-willmar-schwabe-india-aviaire-dilution:\u003C\u002Fp>\u003Cul>\u003Cli>“Dr. Willmar Schwabe India Aviaire Dilution is a powerful homeopathy medicine, recommended for treating tuberculosis.”\u003C\u002Fli>\u003Cli>“It is helpful in curing respiratory disorders after measles.”\u003C\u002Fli>\u003Cli>“Provides support in treatment of tuberculosis”\u003C\u002Fli>\u003Cli>“Relieves difficulties in breathing”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Himalaya Pure Herbs Arjuna Cardiac Wellness\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fhimalaya-pure-herbs-arjuna-cardiac-wellness:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Regulates circulation”\u003Cbr>o “Arjuna is well known for its beneficial effect on blood circulation.”\u003C\u002Fli>\u003Cli>“Arjuna helps in improving coronary artery blood flow, reducing the chances of clot formation and protects the heart muscles.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Muniyal Muniojus Tablets\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fmuniyal-muniojus-tablets-100-tabs:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Supportive Therapy for Immune Deficiency Syndrome”\u003C\u002Fli>\u003Cli>“Studies have proved that Muniojus reduces viral load.”\u003C\u002Fli>\u003Cli>“The ingredients improve host resistance by reducing disease progression and increasing CD cell counts.”\u003C\u002Fli>\u003Cli>“Improves non-specific &amp; acquired immunity-deficiency, which is seen in HIV infections”\u003C\u002Fli>\u003Cli>“Helps in preventing opportunistic infections”\u003C\u002Fli>\u003Cli>“Acts as an antioxidant”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Mohammedia Kalonji Oil\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fmohammedia-kalonji-oil:\u003C\u002Fp>\u003Cul>\u003Cli>“Mohammedia Oil is useful in allergies, joint pains, arthritis stomach problems, kidney pain and infection, headache, falling of hair, piles, earache, dental disease, anaemia, cough, skin diseases, lack of sleep, acidity, constipation etc”\u003C\u002Fli>\u003Cli>“Mohammedia Kalonji oil prevents hair loss”\u003C\u002Fli>\u003Cli>“Kalonji oil for Asthma treatment”\u003C\u002Fli>\u003Cli>“Kalonji oil to cure joint pain”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Patanjali Divya Godhan Ark (Gaumutra)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fpatanjali-divya-godhan-ark-gaumutra-450-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Divya Godhan Ark is an ancient Ayurvedic medicine made by extracting the goodness from gomutra or cow urine. It has multiple benefits and cures a variety of serious ailments.”\u003C\u002Fli>\u003Cli>“It gives you relief from problems of liver and stomach. It cures eczema, controls diabetes and cancer.”\u003C\u002Fli>\u003Cli>“Get holistic cure and experience Ayurvedic healing at its best.”\u003C\u002Fli>\u003Cli>“Diseases curable by cow urine[:] cancer . . . tumor . . . diabetes . . . dysentery . . . measles . . . high blood pressure . . . syphilis . . . leprosy”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Himalaya Ophthacare Eye Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fhimalaya-ophthacare-eye-drops-1:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Relieves eye strain, redness and dryness.”\u003C\u002Fli>\u003Cli>“Himalaya Ophthacare Eye Drops helps to keep eyes safe.”\u003C\u002Fli>\u003Cli>“Honey helps to soothing effect on the eyes.”\u003C\u002Fli>\u003Cli>“Damask rose has cooling properties.”\u003C\u002Fli>\u003Cli>“Helps to keep the eyes safe”\u003C\u002Fli>\u003Cli>“Provides relief to those wearing lenses”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Patanjali Drishti Eye Drop\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fpatanjali-drishti-eye-drop:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Indication: . . . Eye disorder and Beneficial for eyes”\u003C\u002Fli>\u003Cli>“Patanjali Drishti Eye Drop is a very effective eye drop for any kind of eye problem. It is very safe to use ayurvedic medicine which also helps in increasing eyesight.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your Organic Wellnesses products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Lord's L 143 Measles Drop,” and “Dr. Willmar Schwabe India Aviaire Dilution” drug products are labeled as homeopathic drugs. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “716154” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Brad Pace, J.D.\u003Cbr>Associate Director\u003Cbr>Office of Unapproved and Labeling Compliance\u003Cbr>Signed on behalf of:\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nVarunKart Group LLC dba Organic Wellnesses\n\n8206 Louisiana Blvd NE, STE A #4959\n\nAlbuquerque, NM 87113\n\nUnited States\n\nsupport@organicwellnesses.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 17, 2025\nRE: 716154\nVarunKart Group LLC:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Forganicwellnesses.com\u002F in September 2025. The FDA has observed that your website offers “Lord's L 143 Measles Drop,” “Dabur Swarna Bhasma,” “Dr. Willmar Schwabe India Aviaire Dilution,” “Himalaya Pure Herbs Arjuna Cardiac Wellness,” “Muniyal Muniojus Tablets,” “Mohammedia Kalonji Oil,” “Patanjali Divya Godhan Ark (Gaumutra),” “Himalaya Ophthacare Eye Drops” and “Patanjali Drishti Eye Drop” (hereinafter Organic Wellnesses products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nYour Organic Wellnesses products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Lord's L 143 Measles Drop,” “Dabur Swarna Bhasma,” “Dr. Willmar Schwabe India Aviaire Dilution,” “Himalaya Pure Herbs Arjuna Cardiac Wellness,” “Muniyal Muniojus Tablets,” “Mohammedia Kalonji Oil,” and “Patanjali Divya Godhan Ark (Gaumutra)” drug products includes claims to cure, mitigate, treat, or prevent serious and\u002For life-threatening conditions such as measles, syphilis, tuberculosis, cancer, diabetes, and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process. In addition, your unapproved “Himalaya Ophthacare Eye Drops” and “Patanjali Drishti Eye Drop” drug products are concerning because ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\nBased on a review of your website, your Organic Wellnesses products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nLord's L 143 Measles Drop\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Flords-l-143-measles-drop-30-ml:\nFrom the product packaging:\no “Measles Drops”\n“It is beneficial for measles and fever\nIt helps to reduce mild to high temperatures\nIt is beneficial for cough, blisters, watery nose, and eyes”\nDabur Swarna Bhasma\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fdabur-swarna-bhasma-500-mgs:\n“This ayurvedic medicine improves muscle strength and helps in all diseases like muscular dystrophy.”\n“Specially prescribed in hemiplegia and complete paralysis.”\n“Effectively treat Malabsorption syndrome, dyspepsia, hiccup, anaemia, dyspnoea, asthma, fever, tissue wasting, tuberculosis, impaired intelligence, epilepsy, rupture \u002F weakness of ligaments, heart disease, disease due to Vata dosha, syphilis, poison, loss of memory, mania, psychosis, hoarseness of voice, diseases of skin, senility\u002Fprogeriasis”\n“Exceptional efficacy in skin ailments and syphilis.”\nDr. Willmar Schwabe India Aviaire Dilution\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fdr-willmar-schwabe-india-aviaire-dilution:\n“Dr. Willmar Schwabe India Aviaire Dilution is a powerful homeopathy medicine, recommended for treating tuberculosis.”\n“It is helpful in curing respiratory disorders after measles.”\n“Provides support in treatment of tuberculosis”\n“Relieves difficulties in breathing”\nHimalaya Pure Herbs Arjuna Cardiac Wellness\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fhimalaya-pure-herbs-arjuna-cardiac-wellness:\nFrom the product packaging:\no “Regulates circulation”\no “Arjuna is well known for its beneficial effect on blood circulation.”\n“Arjuna helps in improving coronary artery blood flow, reducing the chances of clot formation and protects the heart muscles.”\nMuniyal Muniojus Tablets\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fmuniyal-muniojus-tablets-100-tabs:\nFrom the product packaging:\no “Supportive Therapy for Immune Deficiency Syndrome”\n“Studies have proved that Muniojus reduces viral load.”\n“The ingredients improve host resistance by reducing disease progression and increasing CD cell counts.”\n“Improves non-specific & acquired immunity-deficiency, which is seen in HIV infections”\n“Helps in preventing opportunistic infections”\n“Acts as an antioxidant”\nMohammedia Kalonji Oil\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fmohammedia-kalonji-oil:\n“Mohammedia Oil is useful in allergies, joint pains, arthritis stomach problems, kidney pain and infection, headache, falling of hair, piles, earache, dental disease, anaemia, cough, skin diseases, lack of sleep, acidity, constipation etc”\n“Mohammedia Kalonji oil prevents hair loss”\n“Kalonji oil for Asthma treatment”\n“Kalonji oil to cure joint pain”\nPatanjali Divya Godhan Ark (Gaumutra)\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fpatanjali-divya-godhan-ark-gaumutra-450-ml:\n“Divya Godhan Ark is an ancient Ayurvedic medicine made by extracting the goodness from gomutra or cow urine. It has multiple benefits and cures a variety of serious ailments.”\n“It gives you relief from problems of liver and stomach. It cures eczema, controls diabetes and cancer.”\n“Get holistic cure and experience Ayurvedic healing at its best.”\n“Diseases curable by cow urine[:] cancer . . . tumor . . . diabetes . . . dysentery . . . measles . . . high blood pressure . . . syphilis . . . leprosy”\nHimalaya Ophthacare Eye Drops\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fhimalaya-ophthacare-eye-drops-1:\nFrom the product packaging:\no “Relieves eye strain, redness and dryness.”\n“Himalaya Ophthacare Eye Drops helps to keep eyes safe.”\n“Honey helps to soothing effect on the eyes.”\n“Damask rose has cooling properties.”\n“Helps to keep the eyes safe”\n“Provides relief to those wearing lenses”\nPatanjali Drishti Eye Drop\nOn the webpage https:\u002F\u002Forganicwellnesses.com\u002Fproducts\u002Fpatanjali-drishti-eye-drop:\nFrom the product packaging:\no “Indication: . . . Eye disorder and Beneficial for eyes”\n“Patanjali Drishti Eye Drop is a very effective eye drop for any kind of eye problem. It is very safe to use ayurvedic medicine which also helps in increasing eyesight.”\nYour Organic Wellnesses products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Lord's L 143 Measles Drop,” and “Dr. Willmar Schwabe India Aviaire Dilution” drug products are labeled as homeopathic drugs. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “716154” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nBrad Pace, J.D.\nAssociate Director\nOffice of Unapproved and Labeling Compliance\nSigned on behalf of:\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","VarunKart Group LLC dba Organic Wellnesses","varunkart-group-llc-dba-organic-wellnesses-716154-11172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvarunkart-group-llc-dba-organic-wellnesses-716154-11172025","2026-10-26T08:10:26.637843+00:00","2025-11-25","716154","2026-08-19T14:13:02.666+00:00","VIA Electronic Mail","2025-11-17",10,{"510k":220,"classification":221,"enforcement":222,"event":223,"event_backfill":224,"pma":225,"warning_letter":226},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]